U.S. patent application number 14/297195 was filed with the patent office on 2014-11-27 for heterocyclic compounds for the treatment of neurological and psychological disorders.
The applicant listed for this patent is Alkermes Pharma Ireland Limited. Invention is credited to Laura Cook Blumberg, Julius F. Remenar, Tarek A. Zeidan.
Application Number | 20140350254 14/297195 |
Document ID | / |
Family ID | 43386893 |
Filed Date | 2014-11-27 |
United States Patent
Application |
20140350254 |
Kind Code |
A1 |
Remenar; Julius F. ; et
al. |
November 27, 2014 |
Heterocyclic Compounds for the Treatment of Neurological and
Psychological Disorders
Abstract
Lactam compounds of Formula I and their use for the treatment of
neurological and psychiatric disorders including schizophrenia,
bipolar disorder, anxiety disorder and insomnia is disclosed.
##STR00001##
Inventors: |
Remenar; Julius F.;
(Framingham, MA) ; Blumberg; Laura Cook; (Lincoln,
MA) ; Zeidan; Tarek A.; (Watertown, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Alkermes Pharma Ireland Limited |
Dublin 4 |
|
IE |
|
|
Family ID: |
43386893 |
Appl. No.: |
14/297195 |
Filed: |
June 5, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13607066 |
Sep 7, 2012 |
8796276 |
|
|
14297195 |
|
|
|
|
12823007 |
Jun 24, 2010 |
8431576 |
|
|
13607066 |
|
|
|
|
61220480 |
Jun 25, 2009 |
|
|
|
61293087 |
Jan 7, 2010 |
|
|
|
Current U.S.
Class: |
544/363 |
Current CPC
Class: |
C07D 413/10 20130101;
C07D 417/14 20130101; A61P 25/28 20180101; C07F 9/6558 20130101;
A61P 25/24 20180101; C07D 215/22 20130101; A61P 25/16 20180101;
C07D 241/04 20130101; C07D 215/227 20130101; C07D 471/04 20130101;
A61K 31/496 20130101; C07D 401/14 20130101; C07D 417/12 20130101;
A61P 25/00 20180101; C07D 263/58 20130101; C07D 401/12 20130101;
A61P 43/00 20180101; A61P 25/22 20180101; C07F 9/65583 20130101;
C07D 413/14 20130101; A61P 25/18 20180101; A61K 31/497 20130101;
A61P 25/20 20180101 |
Class at
Publication: |
544/363 |
International
Class: |
C07D 215/22 20060101
C07D215/22 |
Claims
1-34. (canceled)
35. A compound of formula: ##STR00946## or a pharmaceutically
acceptable salt thereof.
36. A compound of formula: ##STR00947## or a pharmaceutically
acceptable salt thereof.
37. A compound of formula: ##STR00948## or a pharmaceutically
acceptable salt thereof.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 13/607,066, filed Sep. 7, 2012, which is a continuation of U.S.
application Ser. No. 12/823,007, filed Jun. 24, 2010, now U.S. Pat.
No. 8,431,576, issued Apr. 30, 2013 which claims the benefit of
U.S. Provisional Application Nos. 61/220,480, filed on Jun. 25,
2009 and 61/293,087, filed on Jan. 7, 2010. The entire teachings of
the above applications are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Currently there are several drugs in clinical use for the
treatment of neurological and psychological disorders including
schizophrenia, bipolor disorder, insomnia and anxiety disorders.
Examples of these compounds include aripiprazole ziprasidone, and
bifeprunox. The chemical structures of these compounds are given
below.
##STR00002##
[0003] Aripiprazole is an atypical antipsychotic used for the
treatment of schizophrenia and schizoaffective disorder. Mace et
al., CNS Drugs, 2009(23), 773-780. Other examples of heterocyclic
derivatives that are useful for the treatment of schizophrenia are
discussed in U.S. Pat. No. 5,350,747, U.S. Pat. No. 5,006,528, U.S.
Pat. No. 7,160,888, and in U.S. Pat. No. 6,127,357. PF-00217830 is
another antipsychotic drug currently undergoing clinical studies
for the treatment of schizophrenia. (NCT00580125) Other
heterocyclic derivatives that have been stated to be useful as
antipsychotic agents are those discussed in WO 93/04684, and
European patent application EP 402644. However, many of the current
antipsychotic drugs suffer from side effects and other undesirable
drawbacks.
[0004] Aripiprazole is a dopamine partial agonist antipsychotic
that is currently approved for clinical use in the United States
and Europe. From the safety perspective it is remarkable that it is
not highly sedative and does not impair the metabolic parameters.
The advantages of a non-sedative and metabolically neutral
antimanic drug are particularly relevant in the long-term, due to
their impact on cognition and quality of life. (Vieta et al. Actas
Esp Psiquiatr 2008:36(3):158-164). However, Aripiprazole is known
to produce injection site reactions. (U.S. Pat. No. 7,115,587).
Ziprasidone is an effective acute and long-term maintenance
treatment option for patients with schizophrenia, schizoaffective
disorder, and schizophric disorder. (Kutcher et al., Neuropsychiatr
Dis Treat., 2005 1(2) 89-108). Ziprasidone users also suffer from
multiple side effects including somnolence. Bifeprunox is known to
improve symptoms in patients with schizophrenia. However, it also
suffers from side effects such as weight gain an increase in
cholesterol levels. (Barbato et al., WO 08/025781). Other
antipsychotic agents also show substantial side effects. For
example, paliperidone and riperidone are associated with weight
gain in patients. (Nussbaum et al., Schizophrenia Bulletin 34(3)
419-422, 2008). Considering the range of side effects associated
with current antipsychotic drugs, it is imperative to develop drugs
with reduced side effects.
[0005] Optimization of a drug's bioavailability has many potential
benefits. For patient convenience and enhanced compliance it is
generally recognized that less frequent dosing is desirable. By
extending the period through which the drug is released, a longer
duration of action per dose is expected. This will then lead to an
overall improvement of dosing parameters such as taking a drug once
a day where it has previously required four times a day dosing or
once a week or even less frequently when daily dosing was
previously required. Many drugs are presently given at a once a day
dosing frequency. Yet, not all of these drugs have pharmacokinetic
properties that are suitable for dosing intervals of exactly
twenty-four hours. Extending the period through which these drugs
are released would also be beneficial.
[0006] One of the fundamental considerations in drug therapy
involves the relationship between blood levels and therapeutic
activity. For most drugs, it is of primary importance that serum
levels remain between a minimally effective concentration and a
potentially toxic level. In pharmacokinetic terms, the peaks and
troughs of a drug's blood levels ideally fit well within the
therapeutic window of serum concentrations. For certain therapeutic
agents, this window is so narrow that dosage formulation becomes
critical.
[0007] In an attempt to address the need for improved
bioavailability, several drug release modulation technologies have
been developed. Enteric coatings have been used as a protector of
pharmaceuticals in the stomach and microencapsulating active agents
using protenoid microspheres, liposomes or polysaccharides have
been effective in abating enzyme degradation of the active agent.
Enzyme inhibiting adjuvants have also been used to prevent enzyme
degradation.
[0008] A wide range of pharmaceutical formulations provide
sustained release through microencapsulation of the active agent in
amides of dicarboxylic acids, modified amino acids or thermally
condensed amino acids. Slow release rendering additives can also be
intermixed with a large array of active agents in tablet
formulations.
[0009] While microencapsulation and enteric coating technologies
impart enhanced stability and time-release properties to active
agent substances these technologies suffer from several
shortcomings. Incorporation of the active agent is often dependent
on diffusion into the microencapsulating matrix, which may not be
quantitative and may complicate dosage reproducibility. In
addition, encapsulated drugs rely on diffusion out of the matrix,
degradation of the matrix, or both which is highly dependent the
chemical properties and on the water solubility of the active
agent. Conversely, water-soluble microspheres swell by an infinite
degree and, unfortunately, may release the active agent in bursts
with limited active agent available for sustained release.
Furthermore, in some technologies, control of the degradation
process required for active agent release is unreliable. Several
implantable drug delivery systems have utilized polypeptide
attachment to drugs. Additionally, other large polymeric carriers
incorporating drugs into their matrices are used as implants for
the gradual release of drug. Yet another technology combines the
advantages of covalent drug attachment with liposome formation
where the active ingredient is attached to highly ordered lipid
films.
[0010] However there is still a need for an active agent delivery
system that is able to deliver certain active agents which have
been heretofore not formulated or difficult to formulate in a
sustained release formulation for release over a sustained period
of time and which is convenient for patient dosing.
[0011] Self administered antipsychotic drugs often suffer from poor
patient compliance in regular administration. Outpatients with
schizophrenia often have problems complying with a regimen of oral
antipsychotic medications. Bartko G et al., Psychiatry Research
1987 (22) 221-227. Thus, it is particularly useful to develop long
acting antipsychotic drugs that can be administered less
frequently.
SUMMARY
[0012] The instant application relates to compounds of Formula I
and their use for the treatment of neurological and psychiatric
disorders including schizophrenia, mania, anxiety and bipolar
disease. In particular the instant application relates to compounds
of Formula I:
##STR00003##
and the geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof, wherein
represents a single or double bond; Semicircle represents an
optionally substituted cycloalkyl, cycloalkenyl, heterocyclyl, aryl
or heteroaryl containing one, two or three rings; A is selected
from absent, optionally substituted alkyl, optionally substituted
alkenyl, optionally substituted alkynyl, --S--, --O--, --S(O)--,
--S(O).sub.2--, --S[C(R.sub.10)(R.sub.11)].sub.u--,
--S(O)[C(R.sub.10)(R.sub.11)].sub.u--,
--S(O).sub.2[C(R.sub.10)(R.sub.11)].sub.u--,
--O[C(R.sub.10)(R.sub.11)].sub.u--, --N(R.sup.10)--,
--N(R.sub.10)--[C(R.sub.10)(R.sub.11)].sub.u--,
--[C(R.sub.10)(R.sub.11)].sub.u;
[0013] wherein each u is independently 1, 2, 3, 4, 5, 6 or 7;
[0014] wherein each R.sub.10 and R.sub.11 is independently absent,
hydrogen, halogen, aliphatic, substituted aliphatic, aryl or
substituted aryl; Cy.sub.1 is an optionally substituted cycloalkyl,
optionally substituted cycloalkenyl, optionally substituted
heterocyclyl or optionally substituted aryl; B is a linker or a
direct bond; D is selected from absent, --O--, --NR.sup.10,
--C(R.sub.10)(R.sub.11)-- and --S--, --S(O)--, --S(O).sub.2--,
--C(O)--; Each G.sub.1 and G.sub.2 is independently selected from
absent, --S--, --O--, --S(O)--, --S(O).sub.2--,
--SC(R.sub.10)(R.sub.11)--, --S(O)C(R.sub.10)(R.sub.11)--,
--S(O).sub.2C(R.sub.10)(R.sub.11)--, --OC(R.sub.10)(R.sub.11)--,
--N(R.sub.10)--, --C(R.sub.10).dbd.C(R.sub.11)--,
--N(R.sub.10)--C(R.sub.10)(R.sub.11)--,
--[C(R.sub.10)(R.sub.11)].sub.t--; [0015] wherein t is 1, 2 or 3;
Each R.sub.1, R.sub.3 and R.sub.4 is independently selected from
absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10,
--N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10,
optionally substituted aliphatic, optionally substituted aryl or
optionally substituted heterocyclyl; Alternatively, two R.sub.3 and
R.sub.4 together form an optionally substituted ring; R.sub.5 is
selected from --CH(R.sub.10)--OR.sub.20,
--CH(R.sub.10)--OC(O)OR.sub.20, --CH(R.sub.10)--OC(O)R.sub.20,
--CH(R.sub.10)--OC(O)NR.sub.20R.sub.21,
--(CH(R.sub.10))--OPO.sub.3MY,
--(CH(R.sub.10))--OP(O)(OR.sub.20)(OR.sub.21),
--[CH(R.sub.10)O]--R.sub.20,
--[CH(R.sub.10)O].sub.z--C(O)OR.sub.20,
--[CH(R.sub.10)O]--C(O)R.sub.20,
--[CH(R.sub.10)O].sub.z--C(O)NR.sub.20R.sub.21,
--[CH(R.sub.10)O]z-OPO.sub.3MY,
--[CH(R.sub.10)O].sub.z--P(O).sub.2(OR.sub.20)M and
--[CH(R.sub.10)O].sub.z--P(O)(OR.sub.20)(OR.sub.21); [0016] wherein
z is 1, 2, 3, 4, 5, 6, or 7; [0017] each R.sub.20 and R.sub.21 is
independently selected from hydrogen, aliphatic, substituted
aliphatic, aryl or substituted aryl; Y and M are the same or
different and each is a monovalent cation; or M and Y together is a
divalent cation; and n, m and q are independently selected from 0,
1, and 2.
[0018] The invention further relates to prodrugs of antipsychotic
drugs that become active agents after in vivo administration. The
invention further relates to sustained release of antipsychotic
drugs.
DETAILED DESCRIPTION FIGURES
[0019] FIG. 1: PXRD spectrum of Compound-7.
[0020] FIG. 2: IR Spectrum of Compound-7.
[0021] FIG. 3: Raman spectrum of Compound-7.
[0022] FIG. 4: TGA thermogram of Compound-7.
[0023] FIG. 5: DSC thermogram of Compound-7.
[0024] FIG. 6: Pharmacodynamic (PD) study of compound-4 in AMPH
induced locomotion model.
[0025] FIG. 7 Pharmacodynamic (PD) study of compound-7 in AMPH
induced locomotion model.
[0026] FIG. 8: Plasma concentration of aripiprazole after
intravenous administration of (0.5 mg/Kg) compound 7 to rats.
[0027] FIG. 9: Plasma concentration of aripiprazole,
dehydroaripiprazole and compound 7 after intramuscular
administration of 30 mg/Kg of compound 7 to dogs.
[0028] One aspect of the present invention provides a compound
having the general Formula I:
##STR00004##
or its geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof, wherein
represents a single or double bond; Semicircle represents an
optionally substituted cycloalkyl, cycloalkenyl, heterocyclyl, aryl
or heteroaryl containing one, two or three rings; A is selected
from absent, optionally substituted alkyl, optionally substituted
alkenyl, optionally substituted alkynyl, --S--, --O--, --S(O)--,
--S(O).sub.2--, --S[C(R.sub.10)(R.sub.11)].sub.u--,
--S(O)[C(R.sub.10)(R.sub.11)].sub.u--,
--S(O).sub.2[C(R.sub.10)(R.sub.11)].sub.u--,
--O[C(R.sub.10)(R.sub.11)].sub.u--, --N(R.sub.10)--,
--N(R.sub.10)--[C(R.sub.10)(R.sub.11)].sub.u--,
--[C(R.sub.10)(R.sub.11)].sub.u; [0029] wherein each u is
independently 1, 2, 3, 4, 5, 6 or 7; [0030] wherein each R.sub.10
and R.sub.11 is independently absent, hydrogen, halogen, aliphatic,
substituted aliphatic, aryl or substituted aryl; Cy.sub.1 is an
optionally substituted cycloalkyl, optionally substituted
cycloalkenyl, optionally substituted heterocyclyl or optionally
substituted aryl; B is a linker or a direct bond; D is selected
from absent, --O--, --NR.sub.10, --C(R.sub.10)(R.sub.11)-- and
--S--, --S(O)--, --S(O).sub.2--, --C(O)--; Each G.sub.1 and G.sub.2
is independently selected from absent, --S--, --O--, --S(O)--,
--S(O).sub.2--, --SC(R.sub.10)(R.sub.11)--,
--S(O)C(R.sub.10)(R.sub.11)--, --S(O).sub.2C(R.sub.10)(R.sub.11)--,
--OC(R.sub.10)(R.sub.11)--, --N(R.sub.10)--,
--C(R.sub.10).dbd.C(R.sub.11)--,
--N(R.sub.10)--C(R.sub.10)(R.sub.11)--,
--[C(R.sub.10)(R.sub.11)].sub.t--; [0031] wherein t is 1, 2 or 3;
Each R.sub.1, R.sub.3 and R.sub.4 is independently selected from
absent, hydrogen, halogen, --OR.sub.10, --SR.sub.10,
--N(R.sub.10)(R.sub.11), --S(O)R.sub.10, --S(O).sub.2R.sub.10,
optionally substituted aliphatic, optionally substituted aryl or
optionally substituted heterocyclyl; Alternatively, two R.sub.3 and
R.sub.4 together form an optionally substituted ring; R.sub.5 is
selected from --CH(R.sub.10)--OR.sub.20,
--CH(R.sub.10)--OC(O)OR.sub.20, --CH(R.sub.10)--OC(O)R.sub.20,
--CH(R.sub.10)--OC(O)NR.sub.20R.sub.21,
--(CH(R.sub.10))--OPO.sub.3MY,
--(CH(R.sub.10))--OP(O)(OR.sub.20)(OR.sub.21),
--[CH(R.sub.10)O]--R.sub.20,
--[CH(R.sub.10)O].sub.z--C(O)OR.sub.20,
--[CH(R.sub.10)O].sub.z--C(O)R.sub.20,
--[CH(R.sub.10)O].sub.z--C(O)NR.sub.20R.sub.21,
--[CH(R.sub.10)O]z-OPO.sub.3MY,
--[CH(R.sub.10)O].sub.z--P(O).sub.2(OR.sub.20)M and
--[CH(R.sub.10)O].sub.z--P(O)(OR.sub.20)(OR.sub.21). [0032] wherein
z is 1, 2, 3, 4, 5, 6, or 7; [0033] each R.sub.20 and R.sub.21 is
independently selected from hydrogen, aliphatic, substituted
aliphatic, aryl or substituted aryl; Y and M are the same or
different and each is a monovalent cation; or M and Y together is a
divalent cation; and n, m and q are independently selected from 0,
1, and 2.
[0034] Substituents indicated as attached through variable points
of attachments can be attached to any available position on the
ring structure.
[0035] In another embodiment, compounds of the present invention
are represented by Formula II as illustrated below, or its
geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof:
##STR00005##
wherein represents a single or double bond; and, R.sub.1, R.sub.3,
R.sub.4, R.sub.5, A, B, D, n, m, p, and q are as defined above;
R.sub.2 selected from absent, hydrogen, halogen, --OR.sub.10,
--SR.sub.10, --N(R.sub.10)(R.sub.11), --S(O)R.sub.10,
--S(O).sub.2R.sub.10, optionally substituted aliphatic, optionally
substituted aryl or optionally substituted heterocyclyl; each
G.sub.3 and G.sub.4 is independently selected from --N--,
--C(R.sub.10)--[C(R.sub.10)(R.sub.11)].sub.a--, wherein a is 0, 1
or 2; and, p is 0, 1, 2, 3 or 4.
[0036] In another embodiment, compounds of the present invention
are represented by Formula III as illustrated below, or its
geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof:
##STR00006##
wherein, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.10,
R.sub.11, A, D, m, p and q are as defined above; and r is 0, 1, 2,
3, 4, 5, 6, 7, 8, 9, 10 or 11.
[0037] In another embodiment, compounds of the present invention
are represented by Formula IV as illustrated below, or its
geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof:
##STR00007##
wherein R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.10, R.sub.11, D,
m, p, q and r are as defined above; each R.sub.6 is independently
selected from hydrogen, halogen, OR.sub.10, SR.sub.10,
NR.sub.10R.sub.11, aliphatic, substituted aliphatic, aromatic,
substituted aromatic, wherein each R.sub.10 and R.sub.11 are
independently hydrogen, halogen, aliphatic, substituted aliphatic
aryl or substituted aryl; or alternatively two adjacent R.sub.6
groups form a second ring; and t and s are independently selected
from 0, 1, and 2.
[0038] In another embodiment, compounds of the present invention
are represented by Formula V as illustrated below, or its geometric
isomers, enantiomers, diastereomers, racemates, pharmaceutically
acceptable salts and solvates thereof:
##STR00008## [0039] wherein represents a single or double bond;
[0040] R.sub.5, is as defined above; and [0041] w is 0, 1, 2, 3, 4,
5, 6, 7, 8, 9, 10 or 11.
[0042] In a preferred embodiment, a compound of Formula VI is
provided below or its geometric isomers, enantiomers,
diastereomers, racemates, pharmaceutically acceptable salts and
solvates thereof:
##STR00009## [0043] wherein, R.sub.1, R.sub.2, R.sub.3, R.sub.5, A,
B, D, G.sub.3, G.sub.4, p, q, R.sub.10 and R.sub.11 are as defined
above; and, [0044] X.sub.1 is --S--, --O--, --NR.sub.10-- or
--C(R.sub.10)(R.sub.11)--.
[0045] In a preferred embodiment, a compound of Formula VII is
provided below or its geometric isomers, enantiomers,
diastereomers, racemates, pharmaceutically acceptable salts and
solvates thereof:
##STR00010##
wherein, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, A, D,
G.sub.3, G.sub.4, m, p, q, r, R.sub.10 and R.sub.11 are as defined
above.
[0046] In a preferred embodiment, a compound of Formula VIII is
provided below or its geometric isomers, enantiomers,
diastereomers, racemates, pharmaceutically acceptable salts and
solvates thereof:
##STR00011##
wherein, R.sub.2, R.sub.3, R.sub.4, R.sub.5, A, D, G.sub.3,
G.sub.4, m, q, r, R.sub.10 and R.sub.11 are as defined above;
and,
X.sub.2 is --S-- or --O--.
[0047] In a preferred embodiment, a compound of Formula IX is
provided below or its geometric isomers, enantiomers,
diastereomers, racemates, pharmaceutically acceptable salts and
solvates thereof:
##STR00012##
wherein, X.sub.2, D, R.sub.2, R.sub.5, r, R.sub.10 and R.sub.11 are
as defined above.
[0048] In a preferred embodiment, a compound of Formula X is
provided below or its geometric isomers, enantiomers,
diastereomers, racemates, pharmaceutically acceptable salts and
solvates thereof:
##STR00013## [0049] wherein, R.sub.5 is as defined above.
[0050] In a preferred embodiment, a compound of Formula XI is
provided below or its geometric isomers, enantiomers,
diastereomers, racemates, pharmaceutically acceptable salts and
solvates thereof:
##STR00014##
wherein, R.sub.1, R.sub.2, R.sub.5, G.sub.3, G.sub.4, X.sub.1, A,
B, D and p are as defined above.
[0051] In a preferred embodiment, a compound of Formula XII is
provided below or its geometric isomers, enantiomers,
diastereomers, racemates, pharmaceutically acceptable salts and
solvates thereof:
##STR00015##
[0052] A more preferred embodiment is a compound of Formula XII
wherein B is a bond; D is absent; G.sub.3 and G.sub.4 are N;
R.sub.2 is H; p is 1; A is alkyl; and R.sub.1 is substituted
phenyl.
[0053] A more preferred embodiment is a compound of Formula XIII
below or its geometric isomers, enantiomers, diastereomers,
racemates, pharmaceutically acceptable salts and solvates
thereof:
##STR00016##
wherein, R.sub.5 is as defined above.
[0054] A preferred embodiment is a compound of Formula XIV below or
its geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof:
##STR00017##
wherein, A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.10,
R.sub.11, G.sub.3, G.sub.4, D, m, p, q, and r as defined above;
and,
X.sub.3 is --CH-- or --N--.
[0055] A more preferred embodiment is a compound where G.sub.3 and
G.sub.3 is --N--.
[0056] A preferred embodiment is a compound of Formula XV below or
its geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof:
##STR00018##
wherein, A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.10,
R.sub.11, G.sub.3, G.sub.4, X.sub.2, m, p, q, and r as defined
above.
[0057] A preferred embodiment is a compound of Formula XVI below or
its geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof:
##STR00019##
wherein, A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.10,
R.sub.11, X.sub.2, m, p, q, and r as defined above.
[0058] A preferred embodiment is a compound of Formula XVII below
or its geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof:
##STR00020##
wherein, R.sub.2, R.sub.5, R.sub.10, R.sub.11, X.sub.2, p and r as
defined above.
[0059] A preferred embodiment is a compound of Formula XVIII below
or its geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts and solvates thereof:
##STR00021##
[0060] In a preferred embodiment, the R.sub.1 moiety is an aryl or
heteroaryl group selected from:
##STR00022## ##STR00023##
wherein R.sub.100 R.sub.101, and R.sub.103 are independently
selected from hydrogen, halogen, optionally substituted
C.sub.1-C.sub.8 alkyl, optionally substituted C.sub.2-C.sub.8
alkenyl, optionally substituted C.sub.2-C.sub.8 alkynyl, optionally
substituted C.sub.3-C.sub.8 cycloalkyl, optionally substituted
C.sub.1-C.sub.8 alkoxy, optionally substituted C.sub.1-C.sub.8
alkylamino and optionally substituted C.sub.1-C.sub.8 aryl.
[0061] In a preferred embodiment, the R.sub.5 moiety is selected
from:
##STR00024##
wherein R.sub.105, R.sub.106 and R.sub.107 are independently
selected from hydrogen, halogen, optionally substituted
C.sub.1-C.sub.24 alkyl, optionally substituted C.sub.2-C.sub.24
alkenyl, optionally substituted C.sub.2-C.sub.24 alkynyl,
optionally substituted C.sub.3-C.sub.24 cycloalkyl, optionally
substituted C.sub.1-C.sub.24 alkoxy, optionally substituted
C.sub.1-C.sub.24 alkylamino and optionally substituted
C.sub.1-C.sub.24 aryl.
[0062] In a more preferred embodiment, R.sub.5 is selected
from:
##STR00025## ##STR00026## ##STR00027##
wherein each x and y is independently an integer between 0 and 30,
and R.sub.105, R.sub.106, and R.sub.107 are as defined above.
[0063] In a more preferred embodiment, x is an integer between 5
and 20.
[0064] In a preferred embodiment, Cy1 is selected from:
##STR00028##
[0065] In a preferred embodiment, the bivalent B is a direct bond,
a straight chain C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkenyl,
C.sub.1-C.sub.10 alkynyl, C.sub.1-C.sub.10 alkoxy,
alkoxyC.sub.1-C.sub.10alkoxy, C.sub.1-C.sub.10 alkylamino,
alkoxyC.sub.1-C.sub.10alkylamino, C.sub.1-C.sub.10
alkylcarbonylamino, C.sub.1-C.sub.10 alkylaminocarbonyl,
aryloxyC.sub.1-C.sub.10alkoxy, aryloxyC.sub.1-C.sub.10alkylamino,
aryloxyC.sub.1-C.sub.10alkylamino carbonyl,
C.sub.1-C.sub.10-alkylaminoalkylaminocarbonyl, C.sub.1-C.sub.10
alkyl(N-alkyl)aminoalkyl-aminocarbonyl, alkylaminoalkylamino,
alkylcarbonylaminoalkylamino, alkyl(N-alkyl)aminoalkylamino,
(N-alkyl)alkylcarbonylaminoalkylamino, alkylaminoalkyl,
alkylaminoalkylaminoalkyl, alkylpiperazinoalkyl, piperazinoalkyl,
alkylpiperazino, alkenylaryloxyC1-C10alkoxy,
alkenylarylaminoC.sub.1-C.sub.10alkoxy,
alkenylaryllalkylaminoC.sub.1-C.sub.10alkoxy,
alkenylaryloxyC.sub.1-C.sub.10alkylamino,
alkenylaryloxyC.sub.1-C.sub.10alkylaminocarbonyl,
piperazinoalkylaryl, heteroarylC.sub.1-C.sub.10alkyl,
heteroarylC.sub.2-C.sub.10alkenyl,
heteroarylC.sub.2-C.sub.10alkynyl,
heteroarylC.sub.1-C.sub.10alkylamino,
heteroarylC.sub.1-C.sub.10alkoxy,
heteroaryloxyC.sub.1-C.sub.10alkyl,
heteroaryloxyC.sub.2-C.sub.10alkenyl,
heteroaryloxyC.sub.2-C.sub.10alkynyl,
heteroaryloxyC.sub.1-C.sub.10alkylamino and
heteroaryloxyC.sub.1-C.sub.10alkoxy.
[0066] In one embodiment, variable R.sub.5 in Formula I and the
geometric isomers, enantiomers, diastereomers, racemates,
pharmaceutically acceptable salts or solvates thereof are selected
from the group set forth in the table below, where the variables Y
and M are the same or different and each is a monovalent cation, or
M and Y together are a divalent cation.
[0067] In a more preferred embodiment, R.sub.5 is selected from
Table 1.
TABLE-US-00001 TABLE 1 ##STR00029## ##STR00030## ##STR00031##
##STR00032## ##STR00033## ##STR00034## ##STR00035## ##STR00036##
##STR00037## ##STR00038## ##STR00039## ##STR00040## ##STR00041##
##STR00042## ##STR00043## ##STR00044## ##STR00045## ##STR00046##
##STR00047## ##STR00048## ##STR00049## ##STR00050## ##STR00051##
##STR00052## ##STR00053## ##STR00054## ##STR00055## ##STR00056##
##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061##
##STR00062## ##STR00063## ##STR00064## ##STR00065## ##STR00066##
##STR00067## ##STR00068## ##STR00069## ##STR00070## ##STR00071##
##STR00072## ##STR00073## ##STR00074## ##STR00075## ##STR00076##
##STR00077## ##STR00078## ##STR00079## ##STR00080## ##STR00081##
##STR00082## ##STR00083## ##STR00084## ##STR00085## ##STR00086##
##STR00087## ##STR00088## ##STR00089## ##STR00090## ##STR00091##
##STR00092## ##STR00093## ##STR00094## ##STR00095## ##STR00096##
##STR00097## ##STR00098## ##STR00099## ##STR00100## ##STR00101##
##STR00102## ##STR00103## ##STR00104## ##STR00105## ##STR00106##
##STR00107## ##STR00108## ##STR00109## ##STR00110## ##STR00111##
##STR00112## ##STR00113## ##STR00114## ##STR00115## ##STR00116##
##STR00117## ##STR00118## ##STR00119## ##STR00120## ##STR00121##
##STR00122## ##STR00123## ##STR00124## ##STR00125## ##STR00126##
##STR00127## ##STR00128## ##STR00129## ##STR00130## ##STR00131##
##STR00132## ##STR00133## ##STR00134## ##STR00135## ##STR00136##
##STR00137## ##STR00138## ##STR00139## ##STR00140## ##STR00141##
##STR00142## ##STR00143## ##STR00144## ##STR00145## ##STR00146##
##STR00147## ##STR00148## ##STR00149## ##STR00150## ##STR00151##
##STR00152##
##STR00153## ##STR00154## ##STR00155## ##STR00156## ##STR00157##
##STR00158## ##STR00159## ##STR00160## ##STR00161## ##STR00162##
##STR00163## ##STR00164## ##STR00165## ##STR00166## ##STR00167##
##STR00168## ##STR00169## ##STR00170## ##STR00171## ##STR00172##
##STR00173## ##STR00174## ##STR00175## ##STR00176## ##STR00177##
##STR00178## ##STR00179## ##STR00180## ##STR00181## ##STR00182##
##STR00183## ##STR00184## ##STR00185## ##STR00186## ##STR00187##
##STR00188## ##STR00189## ##STR00190## ##STR00191## ##STR00192##
##STR00193## ##STR00194## ##STR00195## ##STR00196## ##STR00197##
##STR00198## ##STR00199## ##STR00200## ##STR00201## ##STR00202##
##STR00203## ##STR00204## ##STR00205## ##STR00206## ##STR00207##
##STR00208## ##STR00209## ##STR00210## ##STR00211## ##STR00212##
##STR00213## ##STR00214## ##STR00215## ##STR00216## ##STR00217##
##STR00218## ##STR00219## ##STR00220## ##STR00221## ##STR00222##
##STR00223## ##STR00224## ##STR00225## ##STR00226## ##STR00227##
##STR00228## ##STR00229## ##STR00230## ##STR00231## ##STR00232##
##STR00233## ##STR00234## ##STR00235## ##STR00236## ##STR00237##
##STR00238## ##STR00239## ##STR00240## ##STR00241## ##STR00242##
##STR00243## ##STR00244## ##STR00245## ##STR00246## ##STR00247##
##STR00248## ##STR00249## ##STR00250## ##STR00251## ##STR00252##
##STR00253## ##STR00254## ##STR00255## ##STR00256## ##STR00257##
##STR00258## ##STR00259## ##STR00260## ##STR00261## ##STR00262##
##STR00263## ##STR00264## ##STR00265## ##STR00266## ##STR00267##
##STR00268## ##STR00269## ##STR00270## ##STR00271## ##STR00272##
##STR00273## ##STR00274## ##STR00275## ##STR00276## ##STR00277##
##STR00278##
##STR00279## ##STR00280## ##STR00281## ##STR00282## ##STR00283##
##STR00284## ##STR00285## ##STR00286## ##STR00287## ##STR00288##
##STR00289## ##STR00290## ##STR00291## ##STR00292## ##STR00293##
##STR00294## ##STR00295## ##STR00296## ##STR00297## ##STR00298##
##STR00299## ##STR00300## ##STR00301## ##STR00302## ##STR00303##
##STR00304## ##STR00305## ##STR00306## ##STR00307## ##STR00308##
##STR00309## ##STR00310## ##STR00311## ##STR00312## ##STR00313##
##STR00314## ##STR00315## ##STR00316## ##STR00317## ##STR00318##
##STR00319## ##STR00320## ##STR00321## ##STR00322## ##STR00323##
##STR00324## ##STR00325## ##STR00326## ##STR00327## ##STR00328##
##STR00329## ##STR00330## ##STR00331## ##STR00332## ##STR00333##
##STR00334## ##STR00335## ##STR00336## ##STR00337## ##STR00338##
##STR00339## ##STR00340## ##STR00341## ##STR00342## ##STR00343##
##STR00344## ##STR00345## ##STR00346## ##STR00347## ##STR00348##
##STR00349## ##STR00350## ##STR00351## ##STR00352## ##STR00353##
##STR00354## ##STR00355## ##STR00356## ##STR00357## ##STR00358##
##STR00359## ##STR00360## ##STR00361## ##STR00362## ##STR00363##
##STR00364## ##STR00365## ##STR00366## ##STR00367## ##STR00368##
##STR00369## ##STR00370## ##STR00371## ##STR00372## ##STR00373##
##STR00374## ##STR00375## ##STR00376## ##STR00377## ##STR00378##
##STR00379## ##STR00380## ##STR00381## ##STR00382## ##STR00383##
##STR00384## ##STR00385## ##STR00386## ##STR00387## ##STR00388##
##STR00389## ##STR00390## ##STR00391## ##STR00392## ##STR00393##
##STR00394## ##STR00395## ##STR00396## ##STR00397## ##STR00398##
##STR00399## ##STR00400## ##STR00401## ##STR00402##
##STR00403##
##STR00404## ##STR00405## ##STR00406## ##STR00407## ##STR00408##
##STR00409## ##STR00410## ##STR00411## ##STR00412## ##STR00413##
##STR00414## ##STR00415## ##STR00416## ##STR00417## ##STR00418##
##STR00419## ##STR00420## ##STR00421## ##STR00422## ##STR00423##
##STR00424## ##STR00425## ##STR00426## ##STR00427## ##STR00428##
##STR00429## ##STR00430## ##STR00431## ##STR00432## ##STR00433##
##STR00434## ##STR00435## ##STR00436## ##STR00437## ##STR00438##
##STR00439## ##STR00440## ##STR00441## ##STR00442##
##STR00443##
[0068] In a more preferred embodiment, R.sub.1 is selected from
Table 2:
TABLE-US-00002 TABLE 2 ##STR00444## ##STR00445## ##STR00446##
##STR00447## ##STR00448## ##STR00449## ##STR00450## ##STR00451##
##STR00452## ##STR00453## ##STR00454## ##STR00455## ##STR00456##
##STR00457## ##STR00458## ##STR00459## ##STR00460## ##STR00461##
##STR00462## ##STR00463## ##STR00464## ##STR00465## ##STR00466##
##STR00467## ##STR00468## ##STR00469## ##STR00470## ##STR00471##
##STR00472## ##STR00473## ##STR00474## ##STR00475## ##STR00476##
##STR00477## ##STR00478## ##STR00479## ##STR00480## ##STR00481##
##STR00482## ##STR00483## ##STR00484## ##STR00485## ##STR00486##
##STR00487## ##STR00488## ##STR00489## ##STR00490## ##STR00491##
##STR00492## ##STR00493## ##STR00494## ##STR00495##
[0069] In a more preferred embodiment, R.sub.1 is selected from
Table 3:
TABLE-US-00003 TABLE 3 ##STR00496## ##STR00497## ##STR00498##
##STR00499## ##STR00500## ##STR00501## ##STR00502## ##STR00503##
##STR00504## ##STR00505## ##STR00506## ##STR00507## ##STR00508##
##STR00509## ##STR00510## ##STR00511## ##STR00512## ##STR00513##
##STR00514## ##STR00515##
[0070] In a more preferred embodiment, R.sub.1 is selected from
Table 4:
TABLE-US-00004 TABLE 4 ##STR00516## ##STR00517## ##STR00518##
##STR00519## ##STR00520## ##STR00521## ##STR00522## ##STR00523##
##STR00524## ##STR00525## ##STR00526## ##STR00527## ##STR00528##
##STR00529## ##STR00530## ##STR00531## ##STR00532## ##STR00533##
##STR00534## ##STR00535## ##STR00536## ##STR00537## ##STR00538##
##STR00539## ##STR00540## ##STR00541## ##STR00542## ##STR00543##
##STR00544## ##STR00545## ##STR00546## ##STR00547## ##STR00548##
##STR00549## ##STR00550## ##STR00551## ##STR00552## ##STR00553##
##STR00554## ##STR00555## ##STR00556## ##STR00557## ##STR00558##
##STR00559##
[0071] In a preferred embodiment, a compound having Formula XIX is
provided:
##STR00560##
wherein R.sub.5 is selected from Table 1. A more preferred compound
is where R.sub.5 is selected from Tables 2-4.
[0072] Representative compounds according to the invention are
those selected from the Table A below or its geometric isomers,
enantiomers, diastereomers, racemates, pharmaceutically acceptable
salts and solvates thereof:
TABLE-US-00005 TABLE A No Structure 1 ##STR00561## 2 ##STR00562## 3
##STR00563## 4 ##STR00564## 5 ##STR00565## 6 ##STR00566## 7
##STR00567## 8 ##STR00568## 9 ##STR00569## 10 ##STR00570## 11
##STR00571## 12 ##STR00572## 13 ##STR00573## 14 ##STR00574## 15
##STR00575## 16 ##STR00576## 17 ##STR00577## 18 ##STR00578## 19
##STR00579## 20 ##STR00580## 21 ##STR00581## 22 ##STR00582## 23
##STR00583## 24 ##STR00584## 25 ##STR00585## 26 ##STR00586## 27
##STR00587## 28 ##STR00588## 29 ##STR00589## 30 ##STR00590## 31
##STR00591## 32 ##STR00592## 33 ##STR00593## 34 ##STR00594## 35
##STR00595## 36 ##STR00596## 37 ##STR00597## 38 ##STR00598## 39
##STR00599## 40 ##STR00600## 41 ##STR00601## 42 ##STR00602## 43
##STR00603## 44 ##STR00604## 45 ##STR00605## 46 ##STR00606## 47
##STR00607## 48 ##STR00608## 49 ##STR00609## 50 ##STR00610## 51
##STR00611## 52 ##STR00612## 53 ##STR00613## 54 ##STR00614## 55
##STR00615## 56 ##STR00616## 57 ##STR00617## 58 ##STR00618## 59
##STR00619## 60 ##STR00620## 61 ##STR00621## 62 ##STR00622## 63
##STR00623## 64 ##STR00624## 65 ##STR00625## 66 ##STR00626## 67
##STR00627## 68 ##STR00628## 69 ##STR00629## 70 ##STR00630## 71
##STR00631## 72 ##STR00632## 73 ##STR00633## 74 ##STR00634## 75
##STR00635## 76 ##STR00636## 77 ##STR00637## 78 ##STR00638## 79
##STR00639## 80 ##STR00640## 81 ##STR00641## 82 ##STR00642## 83
##STR00643## 84 ##STR00644## 85 ##STR00645## 86 ##STR00646## 87
##STR00647## 88 ##STR00648## 89 ##STR00649## 90 ##STR00650## 91
##STR00651## 92 ##STR00652## 93 ##STR00653## 94 ##STR00654## 95
##STR00655## 96 ##STR00656## 97 ##STR00657## 98 ##STR00658## 99
##STR00659## 100 ##STR00660## 101 ##STR00661## 102 ##STR00662## 103
##STR00663## 104 ##STR00664## 105 ##STR00665## 106 ##STR00666## 107
##STR00667## 108 ##STR00668## 109 ##STR00669## 110 ##STR00670## 111
##STR00671## 112 ##STR00672## 113 ##STR00673## 114 ##STR00674## 115
##STR00675## 116 ##STR00676## 117 ##STR00677## 118 ##STR00678##
[0073] In a preferred embodiment, a compound having Formula XX is
provided:
##STR00679##
wherein R.sub.5 is selected from Table 1.
[0074] Representative compounds according to the invention are
those selected from the Table B below or its geometric isomers,
enantiomers, diastereomers, racemates, pharmaceutically acceptable
salts and solvates thereof:
TABLE-US-00006 TABLE B No Structure 150 ##STR00680## 151
##STR00681## 152 ##STR00682## 153 ##STR00683## 154 ##STR00684## 155
##STR00685## 156 ##STR00686## 157 ##STR00687## 158 ##STR00688## 159
##STR00689## 160 ##STR00690## 161 ##STR00691## 162 ##STR00692## 163
##STR00693## 164 ##STR00694## 165 ##STR00695## 166 ##STR00696## 167
##STR00697## 168 ##STR00698## 169 ##STR00699## 170 ##STR00700## 171
##STR00701## 172 ##STR00702## 173 ##STR00703## 174 ##STR00704## 175
##STR00705## 176 ##STR00706## 177 ##STR00707## 178 ##STR00708## 179
##STR00709## 180 ##STR00710## 181 ##STR00711## 182 ##STR00712## 183
##STR00713## 184 ##STR00714## 185 ##STR00715## 186 ##STR00716## 187
##STR00717## 188 ##STR00718## 189 ##STR00719## 190 ##STR00720## 191
##STR00721## 192 ##STR00722## 193 ##STR00723## 194 ##STR00724## 195
##STR00725## 196 ##STR00726## 197 ##STR00727## 198 ##STR00728## 199
##STR00729## 200 ##STR00730## 201 ##STR00731## 202 ##STR00732## 203
##STR00733## 204 ##STR00734## 205 ##STR00735## 206 ##STR00736## 207
##STR00737## 208 ##STR00738## 209 ##STR00739## 210 ##STR00740## 211
##STR00741## 212 ##STR00742## 213 ##STR00743## 214 ##STR00744## 215
##STR00745## 216 ##STR00746## 217 ##STR00747## 218 ##STR00748## 219
##STR00749## 220 ##STR00750## 221 ##STR00751## 222 ##STR00752## 223
##STR00753## 224 ##STR00754## 225 ##STR00755## 226 ##STR00756## 227
##STR00757## 228 ##STR00758## 229 ##STR00759## 230 ##STR00760## 231
##STR00761## 232 ##STR00762## 233 ##STR00763## 234 ##STR00764## 235
##STR00765## 236 ##STR00766## 237 ##STR00767## 238 ##STR00768## 239
##STR00769## 240 ##STR00770## 241 ##STR00771## 242 ##STR00772## 243
##STR00773## 244 ##STR00774## 245 ##STR00775## 246 ##STR00776## 247
##STR00777## 248 ##STR00778## 249 ##STR00779## 250 ##STR00780## 251
##STR00781## 252 ##STR00782## 253 ##STR00783## 254 ##STR00784## 255
##STR00785## 256 ##STR00786## 257 ##STR00787## 258 ##STR00788## 259
##STR00789## 260 ##STR00790## 261 ##STR00791## 262 ##STR00792## 263
##STR00793## 264 ##STR00794## 265 ##STR00795## 266 ##STR00796## 267
##STR00797##
[0075] In a preferred embodiment, a compound having Formula XXI is
provided:
##STR00798##
wherein R.sub.5 is selected from Table-1. In a more preferred
compound R.sub.5 is selected from Tables 2-4.
[0076] Representative compounds according to the invention are
those selected from the Table C below or its geometric isomers,
enantiomers, diastereomers, racemates, pharmaceutically acceptable
salts, prodrugs and solvates thereof:
TABLE-US-00007 TABLE C No. Structure 300 ##STR00799## 301
##STR00800## 302 ##STR00801## 303 ##STR00802## 304 ##STR00803## 305
##STR00804## 306 ##STR00805## 307 ##STR00806## 308 ##STR00807## 309
##STR00808## 310 ##STR00809## 311 ##STR00810## 312 ##STR00811## 313
##STR00812## 314 ##STR00813## 315 ##STR00814## 316 ##STR00815## 317
##STR00816## 318 ##STR00817## 319 ##STR00818## 320 ##STR00819## 321
##STR00820## 322 ##STR00821## 323 ##STR00822## 324 ##STR00823## 325
##STR00824## 326 ##STR00825## 327 ##STR00826## 328 ##STR00827## 329
##STR00828## 330 ##STR00829## 331 ##STR00830## 332 ##STR00831## 333
##STR00832## 334 ##STR00833## 335 ##STR00834## 336 ##STR00835## 337
##STR00836## 338 ##STR00837## 339 ##STR00838## 340 ##STR00839## 341
##STR00840## 342 ##STR00841## 343 ##STR00842## 344 ##STR00843## 345
##STR00844## 346 ##STR00845## 347 ##STR00846## 348 ##STR00847## 349
##STR00848## 350 ##STR00849## 351 ##STR00850## 352 ##STR00851## 353
##STR00852## 354 ##STR00853## 355 ##STR00854## 356 ##STR00855## 357
##STR00856##
[0077] In a preferred embodiment, a compound having Formula XXII is
provided:
##STR00857##
wherein R.sub.5 is selected from Table 1. In a more preferred
compound R.sub.5 is selected from Tables 2-4.
[0078] Representative compounds according to the invention are
those selected from the Table D below or its geometric isomers,
enantiomers, diastereomers, racemates, pharmaceutically acceptable
salts and solvates thereof:
TABLE-US-00008 TABLE D No. Structure 400 ##STR00858## 401
##STR00859## 402 ##STR00860## 403 ##STR00861## 404 ##STR00862## 405
##STR00863## 406 ##STR00864## 407 ##STR00865## 408 ##STR00866## 409
##STR00867## 410 ##STR00868## 411 ##STR00869## 412 ##STR00870## 413
##STR00871## 414 ##STR00872## 415 ##STR00873## 416 ##STR00874## 417
##STR00875## 418 ##STR00876## 419 ##STR00877## 420 ##STR00878## 421
##STR00879## 422 ##STR00880## 423 ##STR00881## 424 ##STR00882## 425
##STR00883## 426 ##STR00884## 427 ##STR00885## 428 ##STR00886## 429
##STR00887## 430 ##STR00888## 431 ##STR00889## 432 ##STR00890## 433
##STR00891## 434 ##STR00892## 435 ##STR00893## 436 ##STR00894## 437
##STR00895##
[0079] In a preferred embodiment a compound of Formula XXII is
provided:
##STR00896##
wherein R.sub.5 is selected from Table 1. In a more preferred
compound R.sub.5 is selected from Tables 2-4.
[0080] Representative compounds according to the invention are
those selected from the Table E below or its geometric isomers,
enantiomers, diastereomers, racemates, pharmaceutically acceptable
salts and solvates thereof:
TABLE-US-00009 TABLE E No. Structure 501 ##STR00897## 502
##STR00898## 503 ##STR00899## 504 ##STR00900## 505 ##STR00901## 506
##STR00902## 507 ##STR00903## 508 ##STR00904## 509 ##STR00905## 510
##STR00906## 511 ##STR00907## 512 ##STR00908## 513 ##STR00909## 514
##STR00910## 515 ##STR00911## 516 ##STR00912## 517 ##STR00913## 518
##STR00914## 519 ##STR00915## 520 ##STR00916## 521 ##STR00917## 522
##STR00918## 523 ##STR00919## 524 ##STR00920## 525 ##STR00921## 526
##STR00922## 527 ##STR00923## 528 ##STR00924## 529 ##STR00925## 530
##STR00926## 531 ##STR00927## 532 ##STR00928## 533 ##STR00929## 534
##STR00930## 535 ##STR00931## 536 ##STR00932## 537 ##STR00933## 538
##STR00934## 539 ##STR00935## 540 ##STR00936##
[0081] In another aspect of the invention a general method to
convert lactam compounds of Formula XXIII with secondary amides to
substituted tertiary amides is provided (Scheme 1).
##STR00937##
[0082] In addition to the reaction of an aldehyde or ketone to
compounds of formula XXIII, other process for converting secondary
lactam groups can be used. For example, alkylation followed by
addition of sodium in inert solvents, or addition of potassium
hydroxide or sodium hydroxide followed by alkyl halide addition can
be used. Microwave based synthetic procedures can also be used to
convert secondary lactams to substituted tertiary lactam compounds
of the instant application. (For a general review see March J.
Advanced Organic Chemistry, Wiley, 1992; Inoue et al., Bull. Chem.
Soc. Jpn., 58, 2721-2722, 1985; Mijin et al., J. Serb. Chem. Soc.,
73(10) 945-950, 2008; Bogdal et al. Molecules, 1999, 4, 333-337;
U.S. Pat. No. 5,041,659).
[0083] The invention further relates the sustained delivery of a
compound of Formula XXIII by the administration of a compound of
Formula I. Upon administration of a compound of Formula I, the
labile R.sub.5 moiety may be cleaved off enzymatically, chemically
or through first phase metabolism giving a compound of Formula
XXIII. Without being bound to any theory, it is postulated that for
some of the compounds of Formula I, the release of a compound of
Formula XXIII upon cleavage of the R.sub.5 moiety results in a
therapeutically active agent. For example such active ingredient
can be aripiprazole, ziprasadone or bifeprunox. In one embodiment,
the sustained release comprises a therapeutically effective amount
of a compound of Formula XXIII in the blood stream of the patient
for a period of at least about 36 hours after administration of the
compound of Formula I. In a preferred embodiment, a compound of the
invention provides sustained delivery of the parent drug (Formula
XXIII) over hours, days, weeks or months when administered
parenterally to a subject. For example, the compounds can provide
sustained delivery of the parent drug for up to 7, 15, 30, 60, 75
or 90 days or longer. Without being bound by theory, it is believed
that the compounds of the invention form an insoluble depot upon
parenteral administration, for example subcutaneous, intramuscular
or intraperitoneal injection.
DEFINITIONS
[0084] Listed below are definitions of various terms used to
describe this invention. These definitions apply to the terms as
they are used throughout this specification and claims, unless
otherwise limited in specific instances, either individually or as
part of a larger group.
[0085] An "aliphatic group" or "aliphatic" is non-aromatic moiety
that may be saturated (e.g. single bond) or contain one or more
units of unsaturation, e.g., double and/or triple bonds. An
aliphatic group may be straight chained, branched or cyclic,
contain carbon, hydrogen or, optionally, one or more heteroatoms
and may be substituted or unsubstituted.
[0086] An aliphatic group, when used as a linker, preferably
contains between about 1 and about 24 atoms, more preferably
between about 4 to about 24 atoms, more preferably between about 4
to about 12 atoms, more typically between about 4 and about 8
atoms. An aliphatic group, when used as a substituent, preferably
contains between about 1 and about 24 atoms, more preferably
between about 1 to about 10 atoms, more preferably between about 1
to about 8 atoms, more typically between about 1 and about 6 atoms.
In addition to aliphatic hydrocarbon groups, aliphatic groups
include, for example, polyalkoxyalkyls, such as polyalkylene
glycols, polyamines, and polyimines, for example. Such aliphatic
groups may be further substituted. It is understood that aliphatic
groups may include alkyl, substituted alkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl groups described herein.
[0087] The term "substituted carbonyl" includes compounds and
moieties which contain a carbon connected with a double bond to an
oxygen atom, and tautomeric forms thereof. Examples of moieties
that contain a substituted carbonyl include aldehydes, ketones,
carboxylic acids, amides, esters, anhydrides, etc. The term
"carbonyl moiety" refers to groups such as "alkylcarbonyl" groups
wherein an alkyl group is covalently bound to a carbonyl group,
"alkenylcarbonyl" groups wherein an alkenyl group is covalently
bound to a carbonyl group, "alkynylcarbonyl" groups wherein an
alkynyl group is covalently bound to a carbonyl group,
"arylcarbonyl" groups wherein an aryl group is covalently attached
to the carbonyl group. Furthermore, the term also refers to groups
wherein one or more heteroatoms are covalently bonded to the
carbonyl moiety. For example, the term includes moieties such as,
for example, aminocarbonyl moieties, (wherein a nitrogen atom is
bound to the carbon of the carbonyl group, e.g., an amide).
[0088] The term "acyl" refers to hydrogen, alkyl, partially
saturated or fully saturated cycloalkyl, partially saturated or
fully saturated heterocycle, aryl, and heteroaryl substituted
carbonyl groups. For example, acyl includes groups such as
(C.sub.1-C.sub.6)alkanoyl (e.g., formyl, acetyl, propionyl,
butyryl, valeryl, caproyl, t-butylacetyl, etc.),
(C.sub.3-C.sub.6)cycloalkylcarbonyl (e.g., cyclopropylcarbonyl,
cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, etc.),
heterocyclic carbonyl (e.g., pyrrolidinylcarbonyl,
pyrrolid-2-one-5-carbonyl, piperidinylcarbonyl,
piperazinylcarbonyl, tetrahydrofuranylcarbonyl, etc.), aroyl (e.g.,
benzoyl) and heteroaroyl (e.g., thiophenyl-2-carbonyl,
thiophenyl-3-carbonyl, furanyl-2-carbonyl, furanyl-3-carbonyl,
1H-pyrroyl-2-carbonyl, 1H-pyrroyl-3-carbonyl,
benzo[b]thiophenyl-2-carbonyl, etc.). In addition, the alkyl,
cycloalkyl, heterocycle, aryl and heteroaryl portion of the acyl
group may be any one of the groups described in the respective
definitions. When indicated as being "optionally substituted", the
acyl group may be unsubstituted or optionally substituted with one
or more substituents (typically, one to three substituents)
independently selected from the group of substituents listed below
in the definition for "substituted" or the alkyl, cycloalkyl,
heterocycle, aryl and heteroaryl portion of the acyl group may be
substituted as described above in the preferred and more preferred
list of substituents, respectively.
[0089] The term "alkyl" embraces linear or branched radicals having
one to about twenty carbon atoms or, preferably, one to about
twelve carbon atoms. More preferred alkyl radicals are "lower
alkyl" radicals having one to about ten carbon atoms. Most
preferred are lower alkyl radicals having one to about eight carbon
atoms. Examples of such radicals include methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
iso-amyl, hexyl and the like.
[0090] The term "alkenyl" embraces linear or branched radicals
having at least one carbon-carbon double bond of two to about
twenty carbon atoms or, preferably, two to about twelve carbon
atoms. More preferred alkenyl radicals are "lower alkenyl" radicals
having two to about ten carbon atoms and more preferably about two
to about eight carbon atoms. Examples of alkenyl radicals include
ethenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The terms
"alkenyl", and "lower alkenyl", embrace radicals having "cis" and
"trans" orientations, or alternatively, "E" and "Z"
orientations.
[0091] The term "alkynyl" embraces linear or branched radicals
having at least one carbon-carbon triple bond of two to about
twenty carbon atoms or, preferably, two to about twelve carbon
atoms. More preferred alkynyl radicals are "lower alkynyl" radicals
having two to about ten carbon atoms and more preferably about two
to about eight carbon atoms. Examples of alkynyl radicals include
propargyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butynyl and
1-pentynyl.
[0092] The term "cycloalkyl" embraces saturated carbocyclic
radicals having three to about twelve carbon atoms. The term
"cycloalkyl" embraces saturated carbocyclic radicals having three
to about twelve carbon atoms. More preferred cycloalkyl radicals
are "lower cycloalkyl" radicals having three to about eight carbon
atoms. Examples of such radicals include cyclopropyl, cyclobutyl,
cyclopentyl and cyclohexyl.
[0093] The term "cycloalkenyl" embraces partially unsaturated
carbocyclic radicals having three to twelve carbon atoms.
Cycloalkenyl radicals that are partially unsaturated carbocyclic
radicals that contain two double bonds (that may or may not be
conjugated) can be called "cycloalkyldienyl". More preferred
cycloalkenyl radicals are "lower cycloalkenyl" radicals having four
to about eight carbon atoms. Examples of such radicals include
cyclobutenyl, cyclopentenyl and cyclohexenyl.
[0094] The term "alkoxy" embraces linear or branched oxy-containing
radicals each having alkyl portions of one to about twenty carbon
atoms or, preferably, one to about twelve carbon atoms. More
preferred alkoxy radicals are "lower alkoxy" radicals having one to
about ten carbon atoms and more preferably having one to about
eight carbon atoms. Examples of such radicals include methoxy,
ethoxy, propoxy, butoxy and tert-butoxy.
[0095] The term "alkoxyalkyl" embraces alkyl radicals having one or
more alkoxy radicals attached to the alkyl radical, that is, to
form monoalkoxyalkyl and dialkoxyalkyl radicals.
[0096] The term "aryl", alone or in combination, means a
carbocyclic aromatic system containing one, two or three rings
wherein such rings may be attached together in a pendent manner or
may be fused. The term "aryl" embraces aromatic radicals such as
phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl.
[0097] The terms "heterocyclyl", "heterocycle" "heterocyclic" or
"heterocyclo" embrace saturated, partially unsaturated and
unsaturated heteroatom-containing ring-shaped radicals, which can
also be called "heterocyclyl", "heterocycloalkenyl" and
"heteroaryl" correspondingly, where the heteroatoms may be selected
from nitrogen, sulfur and oxygen. Examples of saturated
heterocyclyl radicals include saturated 3 to 6-membered
heteromonocyclic group containing 1 to 4 nitrogen atoms (e.g.
pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.);
saturated 3 to 6-membered heteromonocyclic group containing 1 to 2
oxygen atoms and 1 to 3 nitrogen atoms (e.g. morpholinyl, etc.);
saturated 3 to 6-membered heteromonocyclic group containing 1 to 2
sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.).
Examples of partially unsaturated heterocyclyl radicals include
dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole.
Heterocyclyl radicals may include a pentavalent nitrogen, such as
in tetrazolium and pyridinium radicals. The term "heterocycle" also
embraces radicals where heterocyclyl radicals are fused with aryl
or cycloalkyl radicals. Examples of such fused bicyclic radicals
include benzofuran, benzothiophene, and the like.
[0098] The term "heteroaryl" embraces unsaturated heterocyclyl
radicals. Examples of heteroaryl radicals include unsaturated 3 to
6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms,
for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl,
pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g.,
4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.)
tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.;
unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen
atoms, for example, indolyl, isoindolyl, indolizinyl,
benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl,
tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.),
etc.; unsaturated 3 to 6-membered heteromonocyclic group containing
an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to
6-membered heteromonocyclic group containing a sulfur atom, for
example, thienyl, etc.; unsaturated 3- to 6-membered
heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3
nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl
(e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl,
etc.) etc.; unsaturated condensed heterocyclyl group containing 1
to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. benzoxazolyl,
benzoxadiazolyl, etc.); unsaturated 3 to 6-membered
heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3
nitrogen atoms, for example, thiazolyl, thiadiazolyl (e.g.,
1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.)
etc.; unsaturated condensed heterocyclyl group containing 1 to 2
sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl,
benzothiadiazolyl, etc.) and the like.
[0099] The term "heterocycloalkyl" embraces heterocyclo-substituted
alkyl radicals. More preferred heterocycloalkyl radicals are "lower
heterocycloalkyl" radicals having one to six carbon atoms in the
heterocyclo radicals.
[0100] The term "alkylthio" embraces radicals containing a linear
or branched alkyl radical, of one to about ten carbon atoms
attached to a divalent sulfur atom. Preferred alkylthio radicals
have alkyl radicals of one to about twenty carbon atoms or,
preferably, one to about twelve carbon atoms. More preferred
alkylthio radicals have alkyl radicals are "lower alkylthio"
radicals having one to about ten carbon atoms. Most preferred are
alkylthio radicals having lower alkyl radicals of one to about
eight carbon atoms. Examples of such lower alkylthio radicals are
methylthio, ethylthio, propylthio, butylthio and hexylthio.
[0101] The terms "aralkyl" or "arylalkyl" embrace aryl-substituted
alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl,
phenylethyl, and diphenylethyl.
[0102] The term "aryloxy" embraces aryl radicals attached through
an oxygen atom to other radicals.
[0103] The terms "aralkoxy" or "arylalkoxy" embrace aralkyl
radicals attached through an oxygen atom to other radicals.
[0104] The term "aminoalkyl" embraces alkyl radicals substituted
with amino radicals. Preferred aminoalkyl radicals have alkyl
radicals having about one to about twenty carbon atoms or,
preferably, one to about twelve carbon atoms. More preferred
aminoalkyl radicals are "lower aminoalkyl" that have alkyl radicals
having one to about ten carbon atoms. Most preferred are aminoalkyl
radicals having lower alkyl radicals having one to eight carbon
atoms. Examples of such radicals include aminomethyl, aminoethyl,
and the like.
[0105] The term "alkylamino" denotes amino groups which are
substituted with one or two alkyl radicals. Preferred alkylamino
radicals have alkyl radicals having about one to about twenty
carbon atoms or, preferably, one to about twelve carbon atoms. More
preferred alkylamino radicals are "lower alkylamino" that have
alkyl radicals having one to about ten carbon atoms. Most preferred
are alkylamino radicals having lower alkyl radicals having one to
about eight carbon atoms. Suitable lower alkylamino may be
monosubstituted N-alkylamino or disubstituted N,N-alkylamino, such
as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino
or the like.
[0106] The term "linker" means an organic moiety that connects two
parts of a compound. Linkers typically comprise a direct bond or an
atom such as oxygen or sulfur, a unit such as NR.sub.8, C(O),
C(O)NH, SO, SO.sub.2, SO.sub.2NH or a chain of atoms, such as
substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, arylalkyl,
arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl,
heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl,
heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl,
cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl,
alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl,
alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl,
alkylheteroarylalkyl, alkylheteroarylalkenyl,
alkylheteroarylalkynyl, alkenylheteroarylalkyl,
alkenylheteroarylalkenyl, alkenylheteroarylalkynyl,
alkynylheteroarylalkyl, alkynylheteroarylalkenyl,
alkynylheteroarylalkynyl, alkylheterocyclylalkyl,
alkylheterocyclylalkenyl, alkylhererocyclylalkynyl,
alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl,
alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl,
alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl,
alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl,
alkynylhereroaryl, which one or more methylenes can be interrupted
or terminated by O, S, S(O), SO.sub.2, N(R.sub.8), C(O),
substituted or unsubstituted aryl, substituted or unsubstituted
heteroaryl, substituted or unsubstituted heterocyclic; where
R.sub.8 is hydrogen, acyl, aliphatic or substituted aliphatic. In
one embodiment, the linker B is between one to about twenty four
atoms, preferably one to about twelve atoms, preferably between
about one to about eight atoms, more preferably one to about six
atoms, and most preferably about four to about six atoms. In some
embodiments, the linker is a C(O)NH(alkyl) chain or an alkoxy
chain.
[0107] The term "substituted" refers to the replacement of one or
more hydrogen radicals in a given structure with the radical of a
specified substituent including, but not limited to: halo, alkyl,
alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio,
alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl,
arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl,
alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl,
aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro,
alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl,
aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl,
alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl,
carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl,
heteroaryl, heterocyclic, and aliphatic. It is understood that the
substituent may be further substituted.
[0108] For simplicity, chemical moieties that are defined and
referred to throughout can be univalent chemical moieties (e.g.,
alkyl, aryl, etc.) or multivalent moieties under the appropriate
structural circumstances clear to those skilled in the art. For
example, an "alkyl" moiety can be referred to a monovalent radical
(e.g. CH.sub.3--CH.sub.2--), or in other instances, a bivalent
linking moiety can be "alkyl," in which case those skilled in the
art will understand the alkyl to be a divalent radical (e.g.,
--CH.sub.2--CH.sub.2--), which is equivalent to the term
"alkylene." Similarly, in circumstances in which divalent moieties
are required and are stated as being "alkoxy", "alkylamino",
"aryloxy", "alkylthio", "aryl", "heteroaryl", "heterocyclic",
"alkyl" "alkenyl", "alkynyl", "aliphatic", or "cycloalkyl", those
skilled in the art will understand that the terms alkoxy",
"alkylamino", "aryloxy", "alkylthio", "aryl", "heteroaryl",
"heterocyclic", "alkyl", "alkenyl", "alkynyl", "aliphatic", or
"cycloalkyl" refer to the corresponding divalent moiety.
[0109] The terms "halogen" or "halo" as used herein, refers to an
atom selected from fluorine, chlorine, bromine and iodine.
[0110] The term "compound" is defined herein to include
pharmaceutically acceptable salts, solvates, hydrates, polymorphs,
enantiomers, diastereoisomers, racemates and the like of the
compounds having a formula as set forth herein.
[0111] The term "sugar" includes aldose, ketoaldose, alditols,
ketoses, aldonic acids, ketoaldonic acids, aldaric acids,
ketoaldaric acids, amino sugars, keto-amino sugars, uronic acids,
ketouronic acids, lactones and keto-lactones. A sugar moiety can be
a triosyl, tetraosyl, pentosyl, hexosyl, heptosyl, octosyl and
nonosyl radicals. Hexosyl sugars include allose, altrose, glucose,
mannose, gulose, idose, galactose, talose, fructose, ribo-hexulose,
arabino-hexulose and lyxo-hexulose. Pentosyl sugars include ribose,
arabinose, xylose, lyxose, ribulose and xylulose.
[0112] Substituents indicated as attached through variable points
of attachments can be attached to any available position on the
ring structure.
[0113] As used herein, the term "effective amount of the subject
compounds," with respect to the subject method of treatment, refers
to an amount of the subject compound which, when delivered as part
of desired dose regimen, brings about management of neurological
and psychiatric disorders to clinically acceptable standards.
[0114] The neurological and psychiatric disorders include, but are
not limited to, disorders such as cerebral deficit subsequent to
cardiac bypass surgery and grafting, stroke, cerebral ischemia,
spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest,
hypoglycemic neuronal damage, dementia (including AIDS-induced
dementia), Alzheimer's disease, Huntington's Chorea, amyotrophic
lateral sclerosis, ocular damage, retinopathy, cognitive disorders,
idiopathic and drug-induced Parkinson's disease, muscular spasms
and disorders associated with muscular spasticity including
tremors, epilepsy, convulsions, cerebral deficits secondary to
prolonged status epilepticus, migraine (including migraine
headache), urinary incontinence, substance tolerance, substance
withdrawal (including, substances such as opiates, nicotine,
tobacco products, alcohol, benzodiazepines, cocaine, sedatives,
hypnotics, etc.), psychosis, schizophrenia, anxiety (including
generalized anxiety disorder, panic disorder, social phobia,
obsessive compulsive disorder, and post-traumatic stress disorder
(PTSD)), mood disorders (including depression, mania, bipolar
disorders), circadian rhythm disorders (including jet lag and shift
work), trigeminal neuralgia, hearing loss, tinnitus, macular
degeneration of the eye, emesis, brain edema, pain (including acute
and chronic pain states, severe pain, intractable pain, neuropathic
pain, inflammatory pain, and post-traumatic pain), tardive
dyskinesia, sleep disorders (including narcolepsy), attention
deficit/hyperactivity disorder, and conduct disorder.
[0115] The term "treatment" refers to any process, action,
application, therapy, or the like, wherein a mammal, including a
human being, is subject to medical aid with the object of improving
the mammal's condition, directly or indirectly.
[0116] As used herein, the term "pharmaceutically acceptable salt"
refers to those salts which are, within the scope of sound medical
judgment, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, allergic
response and the like, and are commensurate with a reasonable
benefit/risk ratio. Pharmaceutically acceptable salts are well
known in the art. For example, S. M. Berge, et al. describes
pharmaceutically acceptable salts in detail in J. Pharmaceutical
Sciences, 66: 1-19 (1977). The salts can be prepared in situ during
the final isolation and purification of the compounds of the
invention, or separately by reacting the free base function with a
suitable organic acid or inorganic acid. Examples of
pharmaceutically acceptable nontoxic acid addition salts include,
but are not limited to, salts of an amino group formed with
inorganic acids such as hydrochloric acid, hydrobromic acid,
phosphoric acid, sulfuric acid and perchloric acid or with organic
acids such as acetic acid, maleic acid, tartaric acid, citric acid,
succinic acid lactobionic acid or malonic acid or by using other
methods used in the art such as ion exchange. Other
pharmaceutically acceptable salts include, but are not limited to,
adipate, alginate, ascorbate, aspartate, benzenesulfonate,
benzoate, bisulfate, borate, butyrate, camphorate,
camphorsulfonate, citrate, cyclopentanepropionate, digluconate,
dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Representative alkali or alkaline earth metal salts include sodium,
lithium, potassium, calcium, magnesium, and the like. Further
pharmaceutically acceptable salts include, when appropriate,
nontoxic ammonium, quaternary ammonium, and amine cations formed
using counterions such as halide, hydroxide, carboxylate, sulfate,
phosphate, nitrate, alkyl having from 1 to 6 carbon atoms,
sulfonate and aryl sulfonate.
[0117] As used herein, the term "pharmaceutically acceptable ester"
refers to esters which hydrolyze in vivo and include those that
break down readily in the human body to leave the parent compound
or a salt thereof. Suitable ester groups include, for example,
those derived from pharmaceutically acceptable aliphatic carboxylic
acids, particularly alkanoic, alkenoic, cycloalkanoic and
alkanedioic acids, in which each alkyl or alkenyl moiety
advantageously has not more than 6 carbon atoms. Examples of
particular esters include, but are not limited to, formates,
acetates, propionates, butyrates, acrylates and
ethylsuccinates.
[0118] As used herein, "pharmaceutically acceptable carrier" is
intended to include any and all solvents, dispersion media,
coatings, antibacterial and antifungal agents, isotonic and
absorption delaying agents, and the like, compatible with
pharmaceutical administration, such as sterile pyrogen-free water.
Suitable carriers are described in the most recent edition of
Remington's Pharmaceutical Sciences, a standard reference text in
the field, which is incorporated herein by reference. Preferred
examples of such carriers or diluents include, but are not limited
to, water, saline, finger's solutions, dextrose solution, and 5%
human serum albumin. Liposomes and non-aqueous vehicles such as
fixed oils may also be used. The use of such media and agents for
pharmaceutically active substances is well known in the art. Except
insofar as any conventional media or agent is incompatible with the
active compound, use thereof in the compositions is contemplated.
Supplementary active compounds can also be incorporated into the
compositions.
[0119] The synthesized compounds can be separated from a reaction
mixture and further purified by a method such as column
chromatography, high pressure liquid chromatography, or
recrystallization. As can be appreciated by the skilled artisan,
further methods of synthesizing the compounds of the formulae
herein will be evident to those of ordinary skill in the art.
Additionally, the various synthetic steps may be performed in an
alternate sequence or order to give the desired compounds.
Synthetic chemistry transformations and protecting group
methodologies (protection and deprotection) useful in synthesizing
the compounds described herein are known in the art and include,
for example, those such as described in R. Larock, Comprehensive
Organic Transformations, VCH Publishers (1989); T. W. Greene and P.
G. M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John
Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's
Reagents for Organic Synthesis, John Wiley and Sons (1994); and L.
Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John
Wiley and Sons (1995), and subsequent editions thereof.
[0120] The compounds described herein may contain one or more
asymmetric centers and thus give rise to enantiomers,
diastereomers, and other stereoisomeric forms that may be defined,
in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)-
or (L)-for amino acids. The present invention is meant to include
all such possible isomers, as well as their racemic and optically
pure forms. Optical isomers may be prepared from their respective
optically active precursors by the procedures described above, or
by resolving the racemic mixtures. The resolution can be carried
out in the presence of a resolving agent, by chromatography or by
repeated crystallization or by some combination of these techniques
which are known to those skilled in the art. Further details
regarding resolutions can be found in Jacques, et al., Enantiomers,
Racemates, and Resolutions (John Wiley & Sons, 1981). When the
compounds described herein contain olefinic double bonds, other
unsaturation, or other centers of geometric asymmetry, and unless
specified otherwise, it is intended that the compounds include both
E and Z geometric isomers and/or cis- and trans-isomers. Likewise,
all tautomeric forms are also intended to be included. The
configuration of any carbon-carbon double bond appearing herein is
selected for convenience only and is not intended to designate a
particular configuration unless the text so states; thus a
carbon-carbon double bond or carbon-heteroatom double bond depicted
arbitrarily herein as trans may be cis, trans, or a mixture of the
two in any proportion.
[0121] The terms "sustained release", "sustained delivery" and
"extended release" are used interchangeably herein to indicate that
compounds of Formula I-XXII, where a labile R.sub.5 moiety is
present, provides for the release of a compound by any mechanism
including slow first order kinetics of absorption or zero order
kinetics of absorption, such that the resulting compounds without
the R.sub.5 moiety is present in the patient, in effective amounts,
for a period of time that is longer than the period of time that
results from administering the corresponding drug without the
R.sub.5 moiety alone (i.e. not as a prodrug of the invention). The
mechanism for timed release may be due to several factors
including, but not limited to, decreasing the solubility upon
conjugation of R.sub.5, resulting in more gradual dissolution and
slower release of the R.sub.5 conjugated compounds (Formula I-XXII)
by the action of serum enzymes or chemical hydrolysis.
[0122] In one embodiment, compounds of Formula I-XXII of the
present invention provide an extended period during which an active
agent is absorbed thereby providing a longer duration of action per
dose than is currently expected. This leads to an overall
improvement of dosing parameters such as, for example taking an
active agent twice a day where it has previously required four
times a day dosing. Alternatively, many active agents presently
given at a once a day dosing frequency, lack the pharmacokinetic
properties suitable for dosing intervals of exactly twelve or
twenty-four hours. The need for an extended period of active agent
adsorption for the current single dose active agent still exists
and would be beneficial as well. "Effective amounts" or a
"therapeutically effective amount" of a prodrug of the invention is
based on that amount of the parent drug which is deemed to provide
clinically beneficial therapy to the patient. However, the prodrug
of the invention provides an effective amount for a longer period
of time per dose than that of the parent drug per the same dose
when delivered alone.
Pharmaceutical Compositions
[0123] The pharmaceutical compositions of the present invention
comprise a therapeutically effective amount of a compound of the
present invention formulated together with one or more
pharmaceutically acceptable carriers or excipients.
[0124] As used herein, the term "pharmaceutically acceptable
carrier or excipient" means a non-toxic, inert solid, semi-solid or
liquid filler, diluent, encapsulating material or formulation
auxiliary of any type. Some examples of materials which can serve
as pharmaceutically acceptable carriers are sugars such as lactose,
glucose and sucrose; cyclodextrins such as alpha-(.alpha.),
beta-(.beta.) and gamma-(.gamma.) cyclodextrins; starches such as
corn starch and potato starch; cellulose and its derivatives such
as sodium carboxymethyl cellulose, ethyl cellulose and cellulose
acetate; powdered tragacanth; malt; gelatin; talc; excipients such
as cocoa butter and suppository waxes; oils such as peanut oil,
cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and
soybean oil; glycols such as propylene glycol; esters such as ethyl
oleate and ethyl laurate; agar; buffering agents such as magnesium
hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water;
isotonic saline; Ringer's solution; ethyl alcohol, and phosphate
buffer solutions, as well as other non-toxic compatible lubricants
such as sodium lauryl sulfate and magnesium stearate, as well as
coloring agents, releasing agents, coating agents, sweetening,
flavoring and perfuming agents, preservatives and antioxidants can
also be present in the composition, according to the judgment of
the formulator.
[0125] The pharmaceutical compositions of this invention may be
administered orally, parenterally, by inhalation spray, topically,
rectally, nasally, buccally, vaginally or via an implanted
reservoir, preferably by oral administration or administration by
injection. The pharmaceutical compositions of this invention may
contain any conventional non-toxic pharmaceutically-acceptable
carriers, adjuvants or vehicles. In some cases, the pH of the
formulation may be adjusted with pharmaceutically acceptable acids,
bases or buffers to enhance the stability of the formulated
compound or its delivery form. The term parenteral as used herein
includes subcutaneous, intracutaneous, intravenous, intramuscular,
intraarticular, intraarterial, intrasynovial, intrasternal,
intrathecal, intralesional and intracranial injection or infusion
techniques.
[0126] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, microemulsions, solutions,
suspensions, syrups and elixirs. In addition to the active
compounds, the liquid dosage forms may contain inert diluents
commonly used in the art such as, for example, water or other
solvents, solubilizing agents and emulsifiers such as ethyl
alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl
alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,
dimethylformamide, oils (in particular, cottonseed, groundnut,
corn, germ, olive, castor, and sesame oils), glycerol,
tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid
esters of sorbitan, and mixtures thereof. Besides inert diluents,
the oral compositions can also include adjuvants such as wetting
agents, emulsifying and suspending agents, sweetening, flavoring,
and perfuming agents.
[0127] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions, may be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0128] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0129] In order to prolong the effect of a drug, it is often
desirable to slow the absorption of the drug from subcutaneous or
intramuscular injection. This may be accomplished by the use of a
liquid suspension of crystalline or amorphous material with poor
water solubility. The rate of absorption of the drug then depends
upon its rate of dissolution, which, in turn, may depend upon
crystal size and crystalline form. Alternatively, delayed
absorption of a parenterally administered drug form is accomplished
by dissolving or suspending the drug in an oil vehicle. Injectable
depot forms are made by forming microencapsule matrices of the drug
in biodegradable polymers such as polylactide-polyglycolide.
Depending upon the ratio of drug to polymer and the nature of the
particular polymer employed, the rate of drug release can be
controlled. Examples of other biodegradable polymers include
poly(orthoesters) and poly(anhydrides). Depot injectable
formulations are also prepared by entrapping the drug in liposomes
or microemulsions that are compatible with body tissues.
[0130] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of this invention with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound.
[0131] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or: a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
[0132] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like.
[0133] The solid dosage forms of tablets, dragees, capsules, pills,
and granules can be prepared with coatings and shells such as
enteric coatings and other coatings well known in the
pharmaceutical formulating art. They may optionally contain
opacifying agents and can also be of a composition that they
release the active ingredient(s) only, or preferentially, in a
certain part of the intestinal tract, optionally, in a delayed
manner. Examples of embedding compositions that can be used include
polymeric substances and waxes.
[0134] Dosage forms for topical or transdermal administration of a
compound of this invention include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or
buffers as may be required. Ophthalmic formulation, ear drops, eye
ointments, powders and solutions are also contemplated as being
within the scope of this invention.
[0135] The ointments, pastes, creams and gels may contain, in
addition to an active compound of this invention, excipients such
as animal and vegetable fats, oils, waxes, paraffins, starch,
tragacanth, cellulose derivatives, polyethylene glycols, silicones,
bentonites, silicic acid, talc and zinc oxide, or mixtures
thereof.
[0136] Powders and sprays can contain, in addition to the compounds
of this invention, excipients such as lactose, talc, silicic acid,
aluminum hydroxide, calcium silicates and polyamide powder, or
mixtures of these substances. Sprays can additionally contain
customary propellants such as chlorofluorohydrocarbons.
[0137] Transdermal patches have the added advantage of providing
controlled delivery of a compound to the body. Such dosage forms
can be made by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux
of the compound across the skin. The rate can be controlled by
either providing a rate controlling membrane or by dispersing the
compound in a polymer matrix or gel.
[0138] For pulmonary delivery, a therapeutic composition of the
invention is formulated and administered to the patient in solid or
liquid particulate form by direct administration e.g., inhalation
into the respiratory system. Solid or liquid particulate forms of
the active compound prepared for practicing the present invention
include particles of respirable size: that is, particles of a size
sufficiently small to pass through the mouth and larynx upon
inhalation and into the bronchi and alveoli of the lungs. Delivery
of aerosolized therapeutics, particularly aerosolized antibiotics,
is known in the art (see, for example U.S. Pat. No. 5,767,068 to
VanDevanter et al., U.S. Pat. No. 5,508,269 to Smith et al., and WO
98/43650 by Montgomery, all of which are incorporated herein by
reference). A discussion of pulmonary delivery of antibiotics is
also found in U.S. Pat. No. 6,014,969, incorporated herein by
reference.
[0139] By a "therapeutically effective amount" of a compound of the
invention is meant an amount of the compound which confers a
therapeutic effect on the treated subject, at a reasonable
benefit/risk ratio applicable to any medical treatment. The
therapeutic effect may be objective (i.e., measurable by some test
or marker) or subjective (i.e., subject gives an indication of or
feels an effect). An effective amount of the compound described
above may range from about 0.1 mg/Kg to about 500 mg/Kg, preferably
from about 1 to about 50 mg/Kg. Effective doses will also vary
depending on route of administration, as well as the possibility of
co-usage with other agents. It will be understood, however, that
the total daily usage of the compounds and compositions of the
present invention will be decided by the attending physician within
the scope of sound medical judgment. The specific therapeutically
effective dose level for any particular patient will depend upon a
variety of factors including the disorder being treated and the
severity of the disorder; the activity of the specific compound
employed; the specific composition employed; the age, body weight,
general health, sex and diet of the patient; the time of
administration, route of administration, and rate of excretion of
the specific compound employed; the duration of the treatment;
drugs used in combination or contemporaneously with the specific
compound employed; and like factors well known in the medical
arts.
[0140] The total daily dose of the compounds of this invention
administered to a human or other animal in single or in divided
doses can be in amounts, for example, from 0.01 to 50 mg/kg body
weight or more usually from 0.1 to 25 mg/kg body weight. Single
dose compositions may contain such amounts or submultiples thereof
to make up the daily dose. In general, treatment regimens according
to the present invention comprise administration to a patient in
need of such treatment from about 10 mg to about 1000 mg of the
compound(s) of this invention per day in single or multiple
doses.
[0141] The compounds of the formulae described herein can, for
example, be administered by injection, intravenously,
intraarterially, subdermally, intraperitoneally, intramuscularly,
or subcutaneously; or orally, buccally, nasally, transmucosally,
topically, in an ophthalmic preparation, or by inhalation, with a
dosage ranging from about 0.1 to about 500 mg/kg of body weight,
alternatively dosages between 1 mg and 1000 mg/dose, according to
the requirements of the particular drug. The methods herein
contemplate administration of an effective amount of compound or
compound composition to achieve the desired or stated effect. The
amount of active ingredient that may be combined with
pharmaceutically excipients or carriers to produce a single dosage
form will vary depending upon the host treated and the particular
mode of administration. A typical preparation will contain from
about 5% to about 95% active compound (w/w). Alternatively, such
preparations may contain from about 20% to about 80% active
compound.
[0142] Lower or higher doses than those recited above may be
required. Specific dosage and treatment regimens for any particular
patient will depend upon a variety of factors, including the
activity of the specific compound employed, the age, body weight,
general health status, sex, diet, time of administration, rate of
excretion, drug combination, the severity and course of the
disease, condition or symptoms, the patient's disposition to the
disease, condition or symptoms, and the judgment of the treating
physician.
[0143] Upon improvement of a patient's condition, a maintenance
dose of a compound, composition or combination of this invention
may be administered, if necessary. Subsequently, the dosage or
frequency of administration, or both, may be reduced, as a function
of the symptoms, to a level at which the improved condition is
retained when the symptoms have been alleviated to the desired
level. Patients may, however, require intermittent treatment on a
long-term basis upon any recurrence of disease symptoms.
EXAMPLES
[0144] The compounds and processes of the present invention will be
better understood in connection with the following examples, which
are intended as an illustration only and not limiting of the scope
of the invention. Various changes and modifications to the
disclosed embodiments will be apparent to those skilled in the art
and such changes and modifications including, without limitation,
those relating to the chemical structures, substituents,
derivatives, formulations and/or methods of the invention may be
made without departing from the spirit of the invention and the
scope of the appended claims. General methodology for the
preparation of lactam compounds can be found in the following
publications: U.S. Pat. No. 7,160,888; U.S. Pat. No. 5,462,934;
U.S. Pat. No. 4,914,094; U.S. Pat. No. 4,234,584; U.S. Pat. No.
4,514,401; U.S. Pat. No. 5,462,934; U.S. Pat. No. 4,468,402; WO
2006/090273 A2; WO 2008/150848 A1; WO 2006/112464 A1; WO
2008/132600 A1.
##STR00938##
Preparation of
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-1-(hydroxymethyl)-3,4--
dihydroquinolin-2(1H)-one (Example 1: Compound A1)
[0145] A mixture of Aripiprazole (20 g, 45 mmol), triethylamine (1
mL, 7.1 mmol), formaldehyde (37% aqueous solution, 70 mL) and
dimethylformamide (200 mL) was heated to 80.degree. C. for 20 h.
The reaction mixture was cooled, diluted with ethyl acetate (400
mL) and washed with water/brine (1:1, 3.times.500 mL). The organic
phase was dried over MgSO.sub.4, filtered and evaporated to dryness
under vacuum to give hemi-aminal A1 as a white solid (18.6 g,
containing 25% Aripiprazole, 65% yield based on A1).
[0146] .sup.1H NMR (CDCl.sub.3, 300 MHz) complex mixture of signals
due to contamination with Aripiprazole, main signal .delta. 5.34
(s, 2H, OHCH.sub.2N); m/z (M.sup.+H) 478 and 480.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl benzylcarbamate (Example 2: Compound 28
[0147] To a solution of hemi-aminal A1 from Example 1 (4 g, 8.4
mmol), 4-dimethylaminopyridine (0.15 g, 1.3 mmol) and triethylamine
(1.1 mL, 7.5 mmol) in dichloromethane (30 mL) was added
benzylisocyanate (1.03 mL, 8.3 mmol) and the reaction mixture
stirred for 24 hours. The reaction mixture was then heated at
35.degree. C. for 20 hours, cooled and washed with water/brine
(1:1, 50 mL). The organic phase was dried over MgSO.sub.4, filtered
and evaporated under vacuum. The residue was further purified by
chromatography on silica eluting with ethyl
acetate/dichloromethane/methanol (1:1:0.1) to give the desired
product as an off white foam (530 mg, 14% yield). .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta. 1.58-1.88 (m, 4H), 2.48 (t, 2H),
2.60-2.72 (m, 6H), 2.85 (m, 2H), 300-3.12 (m, 4H), 3.96 (t, 2H),
4.40 (d, 2H), 5.13 (NH), 5.96 (s, 2H), 6.58 (dd, 1H), 6.79 (d, 1H),
6.92-6.98 (m, 1H), 7.04 (d, 1H), 7.12-7.16 (m, 1H), 7.23-7.35 (m,
6H); m/z (M.sup.+H) 611.12 and 613.10.
[0148] The following compounds were prepared in an analogous
fashion to Example 2.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl ethyl carbonate (Example 3: Compound 79
[0149] The desired product was isolated as a yellow oil (830 mg,
24% yield). .sup.1H NMR (d.sub.6-DMSO, 300 MHz) .delta. 1.78 (t,
3H), 1.52-1.61 (m, 2H), 1.63-1.76 (m, 2H), 2.31-2.40 (m, 2H),
2.40-2.60 (m, 6H), 2.73-2.80 (m, 2H), 2.91-2.99 (m, 4H), 3.96 (t,
3H), 4.11 (q, 2H), 5.87 (s, 2H), 6.60-6.70 (m, 2H), 7.07-7.12 (m,
2H), 7.24-7.30 (m, 2H); m/z (M.sup.+H) 550.48 and 552.40.
butyl(7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydro-
quinolin-1(2H)-yl)methyl carbonate (Example 4: Compound 80)
[0150] The desired product was isolated as a yellow oil (750 mg,
21% yield). .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 0.92 (t, 3H),
1.33-1.45 (m, 2H), 1.59-1.80 (m, 4H), 1.80-1.92 (m, 2H), 2.49 (t,
2H), 2.58-2.75 (m, 6H), 2.85 (t, 2H), 3.00-3.13 (m, 4H), 3.98 (t,
2H), 4.18 (t, 2H), 5.92 (s, 2H), 6.58 (dd, 1H), 6.67 (d, 1H),
6.92-6.99 (m, 1H), 7.03 (dd, 1H), 7.10-7.20 (m, 2H); m/z (M.sup.+H)
578.10 and 580.08.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl hexyl carbonate (Example 5: Compound 81
[0151] The desired product was isolated as a yellow oil (1.77 g,
62% yield). .sup.1H NMR (d.sub.6-DMSO, 300 MHz) .delta. 0.80 (t,
3H), 1.15-1.30 (m, 6H), 1.50-1.60 (m, 4H), 1.65-1.73 (m, 2H), 2.35
(t, 2H), 2.41-2.60 (m, 6H), 2.78 (t, 2H), 2.88-3.00 (m, 4H), 3.95
(t, 2H), 4.06 (t, 2H), 5.86 (s, 2H), 6.60-6.70 (m, 2H), 7.05-7.15
(m, 2H), 7.22-7.28 (m 2H); m/z (M.sup.+H) 606.15 and 608.15.
decyl(7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydro-
quinolin-1(2H)-yl)methyl carbonate (Example 6: Compound 82)
[0152] The desired product was isolated as a yellow oil (1.42 g,
46% yield). .sup.1H NMR (d.sub.6-DMSO, 300 MHz) .delta. 0.79 (m,
3H), 1.13-1.30 (m, 14H), 1.48-1.60 (m, 4H), 1.65-1.75 (m, 2H), 2.33
(t, 2H), 2.41-2.60 (m, 6H), 2.72-2.80 (m, 2H), 2.89-2.98 (m, 4H),
3.95 (t, 2H), 4.05 (t, 2H), 5.86 (s, 2H), 6.60-6.70 (m, 2H),
7.05-7.13 (m, 2H), 7.22-7.28 (m, 2H); m/z (M.sup.+H) 662.56 and
664.54.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl hexadecyl carbonate (Example 7: Compound 83
[0153] The desired product was isolated as a yellow oil (1.55 g,
44% yield). .sup.1H NMR (d.sub.6-DMSO, 300 MHz) .delta. 0.80 (t,
3H), 1.10-1.29 (m, 26H), 1.49-1.60 (m, 4H), 1.65-1.75 (m, 2H), 2.33
(t, 2H), 2.43-2.55 (m, 6H), 2.78 (t, 2H), 2.90-2.95 (m, 4H), 3.95
(t, 2H), 4.05 (t, 2H), 5.84 (s, 2H), 6.60-6.68 (m, 2H), 7.05-7.12
(m, 2H), 7.24-7.29 (m, 2H); m/z (M-C.sub.10H.sub.20).sup.+ 606.52
and 608.54.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl morpholine-4-carboxylate (Example 8: Compound
49
[0154] The desired product was isolated as a yellow oil (1.52 g,
55% yield). .sup.1H NMR (d.sub.6-DMSO, 300 MHz) .delta. 1.50-1.75
(m, 4H), 2.35 (t, 2H), 2.42-2.61 (m, 6H), 2.70-2.82 (m, 2H),
2.88-3.00 (m, 4H), 3.26-3.40 (m, 4H), 3.40-3.60 (m, 4H), 3.94 (t,
2H), 5.81 (s, 2H), 6.61 (dd, 1H), 6.68 (d, 1H), 7.05-7.13 (m, 2H),
7.20-7.30 (m, 2H); m/z (M.sup.+H) 591.11 and 593.15.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl diethylcarbamate (Example 9: Compound 84
[0155] The desired product was isolated as a yellow oil (0.83 g,
31% yield). .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.00-1.20 (m,
6H), 1.65-1.88 (m, 4H), 2.45-2.52 (m, 2H), 2.58-2.83 (m, 6H),
2.82-2.90 (m, 2H), 3.00-3.12 (m, 4H), 3.18-3.38 (m, 4H), 3.97 (t,
2H), 5.91 (s, 2H), 6.58 (dd, 1H), 6.77 (d, 1H), 6.94-6.98 (m, 1H),
7.06 (d, 1H), 7.15-7.20 (m, 2H); m/z (M.sup.+H) 577.48 and
579.46.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl isopentyl carbonate (Example 10: Compound 84
[0156] To a solution of phosgene (20% in toluene, 54 mL, 110 mmol)
in tetrahydrofuran (100 mL) was added a solution of
3-methyl-1-butanol (1.7 mL, 15.7 mmol) in tetrahydrofuran (50 mL)
over 1 hour. After 4 hours the volatiles were removed under vacuum
and the residue added to a solution of the hemi-aminal A1 (3 g, 4.7
mmol), 4-dimethylaminopyridine (0.3 g, 1.9 mmol), pyridine (10 mL)
and triethylamine (1.3 mL, 9.4 mmol) in dichloromethane (30 mL).
After being stirred for 72 hours, the reaction mixture was diluted
with ethyl acetate (100 mL) and washed with 5% aqueous
NaHCO.sub.3/brine (1:1, 100 mL). The organic phase was dried over
MgSO.sub.4, filtered and evaporated under vacuum. The residue was
further purified by chromatography on silica eluting with ethyl
acetate/dichloromethane/methanol (1:1:0.1) to give the desired
product as a yellow oil (1.54 g, 55% yield). .sup.1H NMR (CDCl3,
300 MHz) .delta. 1.90-1.95 (m, 6H), 1.50-1.60 (m, 4H), 1.65-1.79
(m, 2H), 1.79-1.89 (m, 2H), 2.50 (t, 2H), 2.60-2.72 (m, 6H),
2.82-2.90 (m, 2H), 3.02-3.11 (m, 4H), 3.98 (t, 2H), 4.21 (t, 2H),
5.92 (s, 2H), 6.56 (dd, 1H), 6.67 (d, 1H), 6.95-7.00 (m, 1H), 7.05
(d, 1H), 7.13-7.19 (m, 2H); m/z (M.sup.+H) 592.48 and 594.46.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl acetate (Example 11: Compound 1
##STR00939##
[0158] A solution of Compound-A1 from Example-1, (50.63 g, 0.105
mol) in anhydrous tetrahydrofuran (THF, 80 mL) was treated with
acetic anhydride (15.3 mL, 0.16 mol) and heated for 2.0 hours at
60.degree. C. (oil-bath). To the above solution, triethylamine (2.0
mL, 0.014 mol) was added and stirred for 16 hours at 60.degree. C.
The solvent was removed using a rotator evaporator. To the
resulting crude mixture, ethyl acetate (150 mL) and heptane (50 mL)
was added. The solution was washed with NaHCO.sub.3 (5% aqueous
solution, 250 mL,). After separation of the two layers, pH of the
aqueous layer was adjusted to above 7. The aqueous layer was
further extracted using the organic mixture. The organic layer was
separated and washed with 5% NaHCO.sub.3 solution, followed by
deionized water, and brine. The solution was dried using anhydrous
MgSO.sub.4, filtered and evaporated under vacuum. The resulting
product was purified using silica gel column chromatography using
ethanol: ethyl acetate (5:95) as the eluent. Fractions containing
the desired product were combined and d-tartaric acid (12.5 g
dissolved in 60:5 ethanol: water) was added, resulting in the
precipitation of the desired product (48.78 g, 89% yield). .sup.1H
NMR (CDCl3, 300 MHz) .delta. 1.73 (m, 2H), 1.84 (m, 2H), 2.12 (s,
3H), 2.50 (t, 2H), 2.68 (m, 6H), 2.87 (dd, 2H), 3.08 (m, 4H), 3.98
(t, 2H), 5.91 (s, 2H), 6.59 (m, 2H), 6.96 (dd, 1H), 7.08 (dd, 1H),
7.15 (m, 2H).
[0159] The following compounds were prepared in an analogous
fashion to Example 11.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl dodecanoate (Example 12: Compound 7
[0160] The desired product was isolated as a crystalline solid (0.3
g, 21% yield). The molecular weight was confirmed by mass
spectrometer analysis. FIG. 2-6 shows the PXRD, IR, Raman, TGA
spectrum of the desired product. .sup.1H NMR (CDCl3, 300 MHz)
.delta. 0.87 (t, 3H), 1.24 (m, 16H), 1.62 (m, 2H), 1.83 (m, 2H),
1.86 (m, 2H), 2.36 (t, 2H), 2.49 (t, 2H), 2.68 (m, 6H), 2.86 (dd,
2H), 3.08 (m, 4H), 3.97 (t, 2H), 5.91 (s, 2H), 6.59 (m, 2H), 6.96
(dd, 1H), 7.07 (dd, 1H), 7.14 (m, 2H).
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl palmitate (Example 13: Compound 10
##STR00940##
[0162] The desired product was isolated as a crystalline solid (4.2
g, 70% yield). The molecular weight (716.6) was confirmed by mass
spectrometer analysis. .sup.1H NMR (CDCl3, 300 MHz) .delta. 0.88
(t, 3H), 1.25 (m, 24H), 1.64 (m, 2H), 1.72 (m, 2H), 1.84 (m, 2H),
2.36 (t, 2H), 2.49 (t, 2H), 2.68 (m, 6H), 2.86 (dd, 2H), 3.08 (m,
4H), 3.97 (t, 2H), 5.92 (br s, 2H), 6.59 (dd, 1H), 6.60 (s, 1H),
6.96 (dd, 1H), 7.07 (d, 1H), 7.14 (m, 2H).
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl decanoate (Example 14: Compound 6
##STR00941##
[0164] The chloromethyl ester above is dried over 4 .ANG. molecular
sieves. A solution of aripiprazole (45 grams, 0.1 mol) in
1,4-dioxane (800 mL) was sonicated to dissolve the aripiprazole
completely, and then treated with NaH (38 g, 0.95 mol, 60%
dispersion) in one portion. After stirring this reaction mixture
for 15 minutes at room temperature, the reaction mixture was
treated dropwise with chloromethyl ester (0.3 mol.) and a catalytic
amount of sodium iodide (0.05 mol.). The resultant cloudy mixture
was heated to 90.degree. C. for 2 hours, cooled to ambient
temperature and poured into water. The product was extracted with
ethyl acetate, and the combined ethyl acetate layers washed with
brine, dried over sodium sulfate, filtered and concentrated under
reduced pressure. Column chromatography over silica gel provided
the desired product (12.5 gram, 70% yield). .sup.1H NMR (CDCl3, 300
MHz) .delta. 0.87 (t, 3H), 1.20 (m, 12H), 1.63 (m, 2H), 1.70 (m,
2H), 1.83 (m, 2H), 2.35 (t, 2H), 2.50 (t, 2H), 2.68 (m, 6H), 2.86
(t, 2H), 3.08 (m, 4H), 3.97 (t, 2H), 5.92 (s, 2H), 6.58 (dd, 1H),
6.61 (d, 1H), 6.94 (dd, 1H), 7.06 (d, 1H), 7.14-7.17 (m, 2H); m/z
(M.sup.+H) 632.88.
[0165] The following compounds (Examples 15-29) were prepared in an
analogous fashion to Example 2:
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl benzoate (Example 15, Compound 31
[0166] The desired product was isolated as a yellow oil.
[0167] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.60-1.85 (m, 4H),
2.45 (t, 2H), 2.55-2.70 (m, 4H), 2.70-2.78 (m, 2H), 2.85-2.92 (m,
2H), 3.00-3.10 (m, 4H), 3.94 (t, 2H), 6.16 (s, 2H), 6.60 (d, 1H),
6.72 (dd, 1H), 6.90-6.95 (m, 1H), 7.05-7.18 (m, 2H), 7.35-7.42 (m,
2H), 7.52-7.60 (m, 1H), 8.00-8.08 (m, 2H). m/z (M.sup.+H)
582.3.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl butyrate (Example 16, Compound 2
[0168] The desired product was isolated by chromatography on silica
eluting with ethyl acetate/dichloromethane/methanol (1:1:0.1) to
give a yellow oil (2.0 g, 87% yield). .sup.1H NMR (CDCl.sub.3, 300
MHz) .delta. 0.94 (t, 3H), 1.60-1.90 (m, 6H), 2.34 (t, 2H), 2.51
(t, 2H), 2.61-2.73 (m, 6H), 2.82-2.90 (m, 2H), 3.02-3.12 (m, 4H),
3.96 (t, 2H), 5.91 (s, 1H), 6.55-6.61 (m, 2H), 6.93-6.98 (m, 1H),
7.05 (d, 1H), 7.11-7.18 (m, 2H). m/z (M.sup.+H) 548.2 and
550.2.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl hexanoate (Example 17, Compound 4
[0169] The desired product was isolated as a yellow solid (3.69 g,
87% yield). .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 0.78 (t, 3H),
1.11-1.28 (m, 4H), 1.40-1.78 (m, 6H), 2.20-2.40 (m, 4H), 2.40-2.60
(m, 6H), 2.73-2.81 (m, 2H), 2.85-3.00 (m, 4H), 3.88-4.00 (m, 2H),
5.75-5.83 (m, 2H), 6.55-6.62 (m, 2H), 7.03-7.12 (m, 2H), 7.20-7.26
(m, 2H). m/z (M.sup.+H) 576.4 and 578.4.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl tetradecanoate (Example 18, Compound 8
[0170] The desired product was isolated as a pale yellow solid (5.3
g, 74% yield). .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 0.87 (t,
3H), 1.07-1.37 (m, 22H), 1.55-1.70 (m, 2H), 1.70-1.90 (m, 4H), 2.34
(t, 2H), 2.53 (t, 2H), 2.65-2.78 (m, 6H), 2.82-2.90 (m, 2H),
3.02-3.12 (m, 4H), 3.96 (t, 2H), 5.91 (s, 2H), 6.55-6.62 (m, 2H),
6.92-6.98 (m, 1H), 7.05 (d, 1H), 7.11-7.18 (m, 2H). m/z (M.sup.+H)
688.4 and 690.4.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl octanoate (Example 19, Compound 5
[0171] The desired product was isolated as a yellow oil (2.2 g, 87%
yield). .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 0.82 (t, 3H),
1.15-1.35 (m, 10H, 1.55-1.87 (m, 6H), 2.34 (t, 2H), 2.53 (t, 2H),
2.65-2.73 (m, 4H), 2.85 (dd, 2H), 3.01-3.11 (m, 4H), 3.95 (t, 2H),
5.85-5.92 (m, 2H), 2.53-2.60 (m, 2H), 6.91-6.97 (m, 1H), 7.05 (d,
1H), 7.10-7.16 (m, 2H). m/z (M.sup.+H) 604.3 and 606.3.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl isopropyl carbonate (Example 20, Compound 48
[0172] The desired product was isolated as an orange oil (2.4 g,
68% yield). .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.31 (d, 6H),
1.62-1.77 (m, 2H), 1.77-1.89 (m, 2H), 2.48 (t, 2H), 2.60-2.71 (m,
6H), 2.81-2.90 (m, 2H), 3.01-3.11 (m, 4H), 3.98 (t, 2H), 4.89-4.97
(m, 1H), 5.92 (s, 2H), 6.57 (d, 1H), 6.68 (d, 1H), 6.91-7.00 (m,
1H), 7.05 (dd, 1H), 7.11-7.18 (m, 2H). m/z (M.sup.+H) 564.3 and
566.3.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl methylcarbamate (Example 21, Compound 47
[0173] The desired product was isolated as a yellow solid (1.3 g,
52% yield). .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.68-1.88 (m,
4H), 2.49 (dd, 2H), 2.60-2.73 (m, 6H), 2.80-2.90 (m, 5H), 3.02-3.12
(m, 4H), 3.95-4.02 (m, 2H), 5.90 (s, 2H), 6.57 (d, 1H), 6.77 (d,
1H), 6.93-6.70 (m, 1H), 7.05 (d, 1H), 7.10-7.19 (m, 2H). m/z
(M.sup.+H) 535.5 and 537.5.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl decylcarbamate (Example 22, Compound 46
[0174] The desired product was isolated as a yellow solid (0.50 g,
14% yield). .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 0.86 (t, 3H),
1.18-1.35 (m, 16H), 1.42-1.53 (m, 2H), 1.67-1.79 (m, 2H), 1.79-1.87
(m, 2H), 2.48 (t, 2H), 2.58-2.72 (m, 4H), 2.80-2.90 (m, 2H),
3.01-3.12 (m, 4H), 3.15-3.22 (m, 2H), 3.98 (t, 2H), 4.78 (NH), 5.90
(s, 2H), 6.58 (d, 1H), 6.78 (d, 1H), 6.93-7.00 (m, 1H), 7.04 (d,
1H), 7.10-7.16 (m, 2H). m/z (M.sup.+H) 661.6 and 663.6.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl isobutyrate (Example 23, Compound 32
[0175] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.18 (d, 6H),
1.68-1.88 (m, 4H), 2.45-2.73 (m, 9H), 2.87 (dd, 2H), 3.03-3.12 (m,
2H), 3.95 (t, 2H), 5.91 (s, 2H), 6.55-6.60 (m, 2H), 6.93-6.97 (m,
1H), 7.04-7.09 (m, 1H), 7.12-7.19 (m, 2H). m/z (M.sup.+H)
548.15.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl cyclopentanecarboxylate (Example 24, Compound
33
[0176] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.47-1.93 (m,
13H), 2.50-2.60 (m, 2H), 2.60-2.90 (m, 8H), 3.02-3.15 (m, 4H), 3.95
(t, 2H), 5.89 (s, 2H), 6.50-6.60 (m, 2H), 6.90-6.95 (m, 1H),
7.02-7.07 (m, 1H), 7.10-7.19 (m, 2H). m/z (M.sup.+H) 574.15.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl cyclobutanecarboxylate (Example 25, Compound
34
[0177] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.82-1.91 (m, 3H),
1.22-1.30 (m, 2H), 1.75-2.05 (m, 6H), 2.05-2.40 (m, 6H), 2.68-2.73
(m, 2H), 2.84-2.90 (m, 2H), 3.06-3.22 (m, 4H), 3.96 (t, 2H), 5.91
(s, 2H), 6.55-6.59 (m, 2H), 6.97 (dd, 1H), 7.07 (d, 1H), 7.12-7.18
(m, 2H). m/z (M.sup.+H) 560.19.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl cyclohexanecarboxylate (Example 26, Compound
35
[0178] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.15-1.35 (m, 3H),
1.35-1.55 (m, 2H), 1.55-1.95 (m, 10H), 2.21-2.40 (m, 1H), 2.52-2.60
(m, 1H), 2.62-3.00 (m, 8H), 3.02-3.12 (m, 4H), 3.95 (t, 2H), 5.89
(s, 2H), 6.50-6.60 (m, 2H), 6.93-6.97 (m, 1H), 7.02-7.06 (m, 1H),
7.10-7.15 (m, 2H). m/z (M.sup.+H) 588.24.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl 2-(2-methoxyethoxy)acetate (Example 27, Compound
40
[0179] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.56-1.90 (m, 6H),
2.43-2.55 (m, 2H), 2.55-2.80 (m, 4H), 2.81-2.90 (m, 2H), 3.37 (s,
3H), 3.55-3.61 (m, 2H), 3.72-3.79 (m, 2H), 4.20 (s, 2H), 5.97 (s,
2H), 6.55-6.59 (m, 2H), 6.91-6.98 (m, 1H), 7.09 (d, 1H), 7.11-7.15
(m, 2H). m/z (M.sup.+H) 594.17.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl 2-(2-(2-methoxyethoxy)ethoxy)acetate (Example
28, Compound 41
[0180] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.65-1.93 (m, 6H),
2.49-2.60 (m, 2H), 2.61-2.77 (m, 4H), 2.81-2.90 (m, 2H), 3.02-3.20
(m, 4H), 3.36 (s, 3H), 3.51-3.57 (m, 2H), 3.60-3.70 (m, 4H),
3.72-3.78 (m, 2H), 3.92-3.99 (m, 2H), 4.20 (s, 2H), 5.97 (s, 2H),
6.55-6.59 (m, 2H), 6.95-6.99 (m, 1H), 7.05-7.09 (m, 1H), 7.11-7.18
(m, 2H). m/z (M.sup.+H) 638.30.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl pivalate (Example 29, Compound 42
[0181] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.21 (s, 9H),
1.65-1.88 (m, 4H), 2.45-2.55 (m, 2H), 2.60-2.73 (m, 6H), 2.82-2.91
(m, 2H), 3.02-3.13 (m, 4H), 3.95 (t, 2H), 5.89 (s, 2H), 6.54-6.60
(m, 2H), 6.92-6.99 (m, 1H), 7.06 (d, 1H), 7.13-7.17 (m, 2H); m/z
(M.sup.+H) 562.39.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl 2-hydroxyethylcarbamate (Example 30, Compound
36
[0182]
2-(((7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-d-
ihydroquinolin-1(2H)-yl)methoxy)carbonylamino)ethyl methacrylate
(2.0 g) was synthesised in a similar manner to Example 2. This was
reacted with 16% NH.sub.3/MeOH at room temperature for 18 hours and
then concentrated at 40.degree. C. The residue was purified by
silica chromatography eluting with 1:1:0.1 to 1:1:0.2
DCM/EtOAc/MeOH. The resulting yellow oil was re-crystallised from
EtOAc/heptane to give the title compound as a white solid (1.2 g,
67%).
[0183] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.60-1.88 (m, 4H),
2.40-2.50 (m, 2H), 2.50-2.75 (m, 6H), 2.75-2.89 (m, 2H), 2.95-3.15
(m, 4H), 3.20-3.40 (m, 2H), 2.58-3.78 (m, 2H), 3.89-4.05 (m, 2H),
5.30-5.45 (m, NH), 5.91 (s, 2H), 6.55 (dd, 1H), 6.73 (d, 1H),
6.91-6.96 (m, 1H), 6.98-7.03 (m, 1H), 7.04-7.18 (m, 2H). m/z
(M.sup.+H) 565.16.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl bis(2-hydroxyethyl)carbamate (Example 31,
Compound 37
[0184] To a solution of hemiaminal A1 (2 g, 0.0042 mol) in
dichloromethane (30 mL) at room temperature was added pyridine
(0.68 mL), followed by p-nitrophenylchloroformate (1.27 g, 0.0063
mol). After 90 minutes diethanolamine (3.5 g, 0.0334 mol) and
triethylamine (1.2 mL, 0.084 mol) were added. After 3 h the
reaction was diluted with dichloromethane and washed with sat.
NaHCO.sub.3, dried over MgSO.sub.4 and evaporated. The residue was
purified on silica eluting with 1:1:0.1 to 1:1:0.2 DCM/EtOAc/MeOH
to give the title compound as a colourless gum (0.83 g, 33%).
[0185] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.70-1.82 (m, 4H),
2.42-2.52 (m, 2H), 2.59-2.79 (m, 6H), 2.80-2.90 (m, 2H), 3.00-3.12
(m, 4H), 3.40-3.48 (m, 2H), 3.50-3.58 (m, 2H), 3.61-3.70 (m, 2H),
3.85-3.90 (m, 2H), 3.99-4.06 (m, 2H), 5.90 (m, 2H), 6.57 (d, 1H),
6.70 (dd, 1H), 6.92-6.98 (m, 1H), 7.07 (d, 1H), 7.10-7.20 (m, 2H).
m/z (M.sup.+H) 609.21.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl 4-methylpiperazine-1-carboxylate (Example 32,
Compound 38
[0186] Compound 141 was synthesised in a similar manner to Example
28. .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.68-1.88 (m, 4H),
2.25-2.42 (m, 7H), 2.45-2.55 (m, 2H), 2.61-2.76 (m, 6H), 2.85 (dd,
2H), 3.02-3.16 (m, 4H), 3.40-3.60 (m, 4H), 3.97 (t, 2H), 5.92 (s,
2H), 6.59 (d, 1H), 6.74 (d, 1H), 6.92-6.98 (m, 1H), 7.02-7.07 (m,
1H), 7.10-7.16 (m, 2H). m/z (M.sup.+H) 604.24.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl 1,4'-bipiperidine-1'-carboxylate (Example 33,
Compound 39
[0187] Compound 142 was synthesised in a similar manner to Example
28.
[0188] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.26-2.06 (m,
14H), 2.31-2.91 (m, 17H), 2.95-3.18 (m, 4H), 3.97 (t, 2H), 4.0-4.37
(m, 2H), 5.91 (s, 2H), 6.58 (dd, 1H), 6.74 (d, 1H), 6.90-6.99 (m,
1H), 7.05 (d, 1H), 7.11-7.18 (m, 2H); m/z (M.sup.+H) 672.25.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-1-(methoxymethyl)-3,4-d-
ihydroquinolin-2(1H)-one (Example 34, Compound 100)
[0189] To a mixture of hemiaminal A1 (2.0 g, 4.2 mmol) in
dichloromethane (20 mL) was added thionyl chloride (1.5 mL, 12.6
mmol) and stirred for 2 h at room temperature. To the reaction
mixture was added methanol (10 mL) and stirred a further 2 h. The
reaction poured into NaHCO.sub.3 (aq) and extracted with
dichloromethane. The organic phase dried over MgSO.sub.4,
evaporated and the residue purified on silica eluting with 1:1:0.1
dichloromethane/ethyl acetate/methanol to give the title compound
as a cream solid (1.3 g, 63%).
[0190] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.65-1.83 (m, 4H),
2.47 (t, 2H), 2.58-2.70 (m, 6H), 2.82 (dd, 2H), 2.99-3.01 (m, 4H),
3.38 (s, 3H), 3.96 (t, 2H), 5.27 (s, 2H), 6.55 (dd, 1H), 6.88 (dd,
1H), 6.91-6.96 (m, 1H), 7.03 (d, 1H), 7.08-7.15 (m, 2H). m/z
(M.sup.+H) 492.05.
1-(7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroqui-
nolin-1(2H)-yl)-2-ethoxy-2-oxoethyl decanoate (Example 35, Compound
111)
[0191] A mixture of Aripiprazole (2.0 g, 4.5 mmol), ethyl
glyoxylate (50% soln. in toluene, 2.7 mL), K.sub.2CO.sub.3 (0.49 g,
3.6 mmol), tetrabutylammonium bromide (0.57 g, 1.8 mmol) and
dichloromethane (20 mL) was heated at reflux for 4 h. The reaction
mixture was cooled and quickly washed with water, dried over
MgSO.sub.4 and filtered. The resulting solution was treated with
pyridine (1.8 mL, 22.2 mmol) and then decanoylchloride (4.6 mL,
22.2 mmol). After being stirred for 3 h, methanol (1 mL) was added
and stirred a further 10 min. The reaction mixture was washed with
sat.NaHCO.sub.3 (aq), dried over MgSO.sub.4 and evaporated. The
residue was purified on silica eluting with 1:1:0.1
dichloromethane/ethyl acetate/methanol to give the title compound
as a yellow oil (1.2 g, 38%).
[0192] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 0.86 (t, 3H), 1.11
(t, 3H), 1.05-1.40 (m, 12H), 1.59-1.75 (m, 2H), 1.75-1.98 (m, 4H),
2.40-2.54 (m, 2H), 2.60-3.07 (m, 10H), 3.15-3.32 (m, 4H), 3.89-3.99
(m, 2H), 4.09-4.21 (m, 2H), 6.57 (dd, 1H), 6.67 (d, 1H), 6.95-7.00
(m, 1H), 7.08 (dd, 1H), 7.12-7.20 (m, 2H), 7.27-7.32 (m, 1H). m/z
(M.sup.+H) 704.38.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl 4-acetamidobutanoate (Example 36, Compound
44
[0193] To a suspension of hemiaminal A1 (2.6 g, 5.5 mmol) in
dichloromethane (30 mL) was added triethylamine (2.3 mL, 16.4
mmol), followed by addition of methanesulfonyl chloride (0.47 g,
6.0 mmol) over 3 min. The reaction mixture was stirred for 25 min
and then N-acetyl-4-aminobutyric acid (1.6 g, 10.1 mmol) added. The
reaction mixture was then heated at reflux for 18 h, cooled and
washed with sat. NaHCO.sub.3 (aq). The organic phase was dried over
MgSO.sub.4, filtered and evaporated. The residue was further
purified on silica eluting with 1:1:0.1 to 1:1:0.2
dichloromethane/ethyl acetate/methanol to give the title compound
as an off white solid (1.1 g, 34%).
[0194] .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 1.70-1.80 (m, 2H),
1.80-1.90 (m, 4H), 1.97 (s, 3H), 2.41 (t, 2H), 2.50-2.57 (m, 2H),
2.60-2.75 (m, 6H), 2.83-2.88 (m, 2H), 3.03-3.12 (m, 4H), 3.24-3.32
(m, 2H), 3.95-4.00 (m, 2H), 5.85-5.92 (m, 3H), 6.58 (d, 2H),
6.92-6.96 (m, 1H), 7.05 (d, 1H), 7.12-7.16 (m, 2H).). m/z
(M.sup.+H) 605.08.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinol-
in-1(2H)-yl)methyl 4-octanamidobutanoate (Example 37, Compound
45
[0195] Compound 149 (1.4 g) was synthesized in a similar manner to
Compound 148.
[0196] .sup.1H NMR (d.sub.6-DMSO, 300 MHz) .delta. 0.79 (t, 3H),
1.10-1.28 (m, 8H), 1.38-1.48 (m, 2H), 1.50-1.77 (m, 6H), 1.93-2.00
(m, 2H), 2.25-2.40 (m, 4H), 2.40-2.60 (m, 6H), 2.72-2.81 (m, 2H),
2.87-3.02 (m, 6H), 3.90-4.00 (m, 2H), 5.82 (s, 2H), 6.58-6.63 (m,
2H), 7.04-7.02 (m, 2H), 7.20-7.30 (m, 2H). m/z (M.sup.+H)
689.47.
5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloro-2-oxoindol-
in-1-yl)methyl hexanoate (Example 38, Compound 322
##STR00942##
[0197] Step 1:
[0198] Thionyl chloride (12.31 g, 103 mmol) followed by catalytic
amount of N,N-dimethyl formamide (DMF, 0.1 mL) was added to a
solution of Hexanoic acid (10 g, 86 mmol) in dichloromethane (DCM,
100 mL) at 25-30.degree. C. The reaction solution was stirred at
same temperature for 2 hours under nitrogen atmosphere, upon
completion of the starting material by TLC analysis. The volatiles
were evaporated under reduced pressure below 40.degree. C., which
provided a viscous liquid material, hexanoyl chloride (about 10.5
g).
Step 2:
[0199] To the above hexanoyl chloride, para formaldehyde (3.8 g,
128 mmol) and anhydrous ZnCl.sub.2 (0.232 g, 17 mmol) were added at
25-30.degree. C. under inert atmosphere and then heated to
90.degree. C. The thick mass was stirred at 90-95.degree. C. for 5
hours, which after cooling provided crude product, chloromethyl
hexanoate which was purified by silica gel column
chromatography.
[0200] .sup.1H-NMR (CDCl3, 500 MHz): .delta. 5.70 (s, 2H),
2.39-2.33 (m, 2H), 1.69-1.61 (m, 2H), 1.33-1.28 (m, 4H), 0.90-0.88
(t, J=7, 3H).
##STR00943##
Step 3:
[0201] Chloromethyl hexanoate (3.18 g, 19.0 mmol) in
dichloromethane (6 mL) was added to a suspension of Ziprasidone
free base (4.0 g, 9.6 mmol), triethyl amine (4.0 mL, 27 mmol) and
4-dimethylamino pyridine (DMAP, 0.708 g, 5 mmol) in dichloride
methane (240 mL) at 25-30.degree. C. The reaction solution was
stirred for 24 h at same temperature. The crude mixture was washed
with water (100 mL) followed by brine solution (100 mL), upon
solvent evaporation under vacuum below 40.degree. C. provided crude
title product, Compound 322, which was further purified by silica
gel column chromatography. (1.4 g, 27% yield).
[0202] .sup.1H-NMR (CDCl3, 500 MHz): .delta. 7.92-7.90 (d, J=7.5,
1H), 7.82-7.80 (d, J=7.5, 1H), 7.48-7.45 (t, J=7.5, 1H), 7.37-7.34
(t, J=7.5, 1H), 7.17 (s, 1H), 7.05 (s, 1H), 5.72 (s, 2H), 3.60-3.55
(m, 6H), 2.98-2.95 (t, J=7.5, 2H), 2.79-2.78 (m, 4H), 2.68-2.65 (t,
J=8.5, 2H), 2.35-2.32 (t, J=7.5, 2H), 1.64-1.61 (t, J=7.5, 2H),
1.29-1.25 (m, 4H), 0.88-0.85 (t, J=7, 3H).
[0203] Mass (m/z)=541 [M.sup.++1].
5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloro-2-oxoindol-
in-1-yl)methyl dodecanoate (Example 39, Compound 324
[0204] Compound 324 was synthesized in a similar manner to Compound
322, Example 38.
[0205] .sup.1H-NMR (CDCl3, 500 MHz): .delta. 7.92-7.90 (d, J=7.5,
1H), 7.82-7.80 (d, J=7.5, 1H), 7.48-7.45 (t, J=7.5, 1H), 7.37-7.34
(t, J=7.5, 1H), 7.17 (s, 1H), 7.05 (s, 1H), 5.72 (s, 2H), 3.60-3.55
(m, 6H), 2.98-2.95 (t, J=8, 2H), 2.79-2.77 (m, 4H), 2.68-2.65 (t,
J=8, 2H), 2.34-2.31 (t, J=7.2H), 1.63-1.60 (m, 2H), 1.24 (s, 16H),
0.89-0.86 (t, J=7, 3H).
[0206] Mass (m/z)=625.5 [M.sup.++1].
5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloro-2-oxoindol-
in-1-yl)methyl palmitate (Example 40, Compound 326
[0207] .sup.1H-NMR (CDCl.sub.3, 500 MHz): .delta. 7.92-7.90 (d,
J=7.5, 1H), 7.82-7.80 (d, J=7.5, 1H), 7.48-7.45 (t, J=7.5, 1H),
7.37-7.34 (t, J=7.5, 1H), 7.17 (s, 1H), 7.05 (s, 1H), 5.72 (s, 2H),
3.60-3.55 (m, 6H), 2.98-2.95 (t, J=8, 2H), 2.79-2.77 (m, 4H),
2.68-2.65 (t, J=8, 2H), 2.34-2.31 (t, J=8, 2H), 1.63-1.56 (m, 2H),
1.25-1.23 (m, 24H), 0.88-0.86 (t, J=7, 2H).
[0208] Mass (m/z)=681.5 [M.sup.++1].
7-[(4-biphenyl-3yl
methyl)piperazin-1-yl]-2-oxobenzo[d]oxazol-3(2H)-yl)methyl acetate
(Example 41, Compound 416
##STR00944##
[0209] Step 1.
[0210] Synthesis of chloromethyl acetate: Acetyl chloride (5 g,
0.06 mol) was added dropwise to a mixture of paraformaldhyde (8.5
g, 0.06 mol) and anhydrous zinc chloride (0.175 g, 0.02 mol) at
0.degree. C. under Argon. The reaction mixture was warmed to room
temperature and stirred for 1 hour, then heated to 90.degree. C.
for 18 hours. The solid was filtered off washed with
dichloromethane, and the filtrate was concentrated under vacuum at
37.degree. C. to provide the desired product (6.6 g, 94% yield).
The product was used directly (without purification) in to next
step and stored with activated molecular sieves (4.degree. A).
Step 2.
[0211] Synthesis of iodomethyl acetate: Sodium iodide (27.6 g, 0.18
mol) was added to a solution of chloromethyl acetate (6.6 g, 0.06
mol) in acetonitrile (66 mL). The reaction flask was covered in
aluminum foil to exclude light and stirred at ambient temperature
for 15 hours. The reaction mixture was partition between
dichloromethane and water, and the aqueous layer was extracted with
dichloromethane. The combine organics were washed with aqueous
saturated NaHCO.sub.3, 10% aqueous sodium sulfite solution, and
brine then dried with sodium sulphate and concentrated to give the
product (1.13 g, 12% yield) as a yellow oil.
Step 3.
[0212] n-Butyl lithium (1.6 M in hexane; 3.8 mL, 0.007 mol) was
added drop wise from a syringe to a stirred solution of bifeprunox
(1.46 g, 0.003 mol) in tetrahydrofuran at -78.degree. C. After 1
hour a solution of iodomethyl acetate (1.13 g, 0.005 mol) was added
drop-wise at -70.degree. C. The reaction mixture was stirred for 15
hours. The reaction mixture was dumped in a saturated aqueous
solution of ammonium chloride and extracted with ethyl acetate. The
combined organic layers were washed with 1N solution of NaOH and
brine, then dried with sodium sulphate and concentrated under
vacuum. Purification by flash chromatography provided compound 416.
(0.25 g, 14% yield). .sup.1H NMR (DMSO, 400 MHz) .delta. 2.034 (s,
3H), 2.565 (s, 4H), 3.183 (s, 4H), 3.597 (s, 2H), 5.765 (s, 2H),
6.696-6.717 (d, 1H), 6.882-6.901 (d, 1H), 7.091-7.182 (t, 1H),
7.315-7.370 (q, 2H), 7.404-7.473 (m, 3H), 7.515-7.555 (d, 1H), 7.59
(d, 1H), 7.639-7.657 (d, 2H). m/z (M+H) 457.
7-[(4-biphenyl-3yl
methyl)piperazin-1-yl]-2-oxobenzo[d]oxazol-3(2H)-yl)methyl butyrate
(Example 42, Compound 417
[0213] Compound 417 was prepared in a similar manner to Example 41
using butanoyl chloride. Purification by flash chromatography
provided the desired product (1.25 g, 45% yield). 1H NMR (DMSO, 400
MHz) .delta. 1.065 (t, 3H), 1.448-1.54 (m, 2H), 2.284-2.320 (t,
2H), 2.564 (s, 4H), 3.184 (s, 4H), 3.597 (s, 2H), 5.787 (s, 2H),
6.694-6.713 (d, 1H), 6.878-6.896 (d, 1H), 7.092-7.133 (t, 1H),
7.315-7.370 (q, 2H), 7.422-7.533 (m, 3H), 7.535-7.555 (d, 1H),
7.639 (d, 1H), 7.657-7.660 (d, 2H). m/z (M+H) 485.
7-[(4-biphenyl-3yl
methyl)piperazin-1-yl]-2-oxobenzo[d]oxazol-3(2H)-yl)methyl
hexanoate (Example 43, Compound 413
[0214] Compound 413 was prepared in a similar manner to Example 41
using hexanoyl chloride. Purification by flash chromatography
provided the desired product (0.6 g, 60% yield). 1H NMR (DMSO, 400
MHz) .delta. 0.774 (t, 3H), 1.114-1.187 (m, 4H), 1.433-1.506 (m,
2H), 2.291-2.328 (t, 2H), 2.564 (s, 4H), 3.182 (s, 4H), 3.597 (s,
2H), 5.783 (s, 2H), 6.693-6.713 (d, 1H), 6.870-6.890 (d, 1H),
7.090-7.130 (t, 1H), 7.314-7.351 (q, 2H), 7.422-7.472 (m, 3H),
7.535-7.554 (d, 1H), 7.589 (d, 1H), 7.638-7.656 (d, 2H). m/z (M+H)
513.
7-[(4-biphenyl-3yl
methyl)piperazin-1-yl]-2-oxobenzo[d]oxazol-3(2H)-yl)methyl
palmitate (Example 44, Compound 422
[0215] Compound 422 was prepared in a similar manner to Example 41
using palmitoyl chloride. Purification by flash chromatography
provided the desired product (0.5 g, 47% yield). 1H NMR (DMSO, 400
MHz) .delta. 0.819 (t, 3H), 1.127-1.302 (m, 22H), 1.437-1.454 (t,
2H), 2.287-2.305 (t, 2H), 2.564 (s, 4H), 3.182 (s, 4H), 3.596 (s,
2H), 5.784 (s, 2H), 6.688-6.708 (d, 1H), 6.863-6.882 (d, 1H),
7.083-7.124 (t, 1H), 7.331-7.368 (q, 2H), 7.400-7.470 (m, 3H),
7.534-7.553 (d, 1H), 7.587 (d, 1H), 7.635-7.653 (d, 2H). m/z (M+H)
653.
7-[(4-biphenyl-3yl
methyl)piperazin-1-yl]-2-oxobenzo[d]oxazol-3(2H)-yl)methyl
decanoate (Example 45, Compound 419
[0216] Compound 419 was prepared in a similar manner to Example 41
using decanoyl chloride. Purification by flash chromatography
provided the desired product (0.8 g, 77% yield). 1H NMR (DMSO, 400
MHz) .delta. 0.795-0.829 (t, 3H), 1.140-1.211 (m, 12H), 1.438-1.471
(t, 2H), 2.288-2.324 (t, 2H), 2.562 (s, 4H), 3.181 (s, 4H), 3.595
(s, 2H), 5.783 (s, 2H), 6.689-6.709 (d, 1H), 6.856-6.884 (d, 1H),
7.083-7.124 (t, 1H), 7.311-7.367 (q, 2H), 7.400-7.470 (m, 3H),
7.533-7.552 (d, 1H), 7.587 (d, 1H), 7.635-7.653 (d, 2H). m/z (M+H)
569.
7-[(4-biphenyl-3yl
methyl)piperazin-1-yl]-2-oxobenzo[d]oxazol-3(2H)-yl)methyl
isobutyrate (Example 46, Compound 414
[0217] Compound 414 was prepared in a similar manner to Example 41
using isobutyryl chloride. Purification by flash chromatography
provided the desired product (0.3 g, 15% yield). 1H NMR (DMSO, 400
MHz) .delta. 1.027-1.044 (d, 6H), 2.478-2.553 (m, 1H), 2.562 (s,
4H), 3.185 (s, 4H), 3.597 (s, 2H), 5.785 (s, 2H), 6.692-6.713 (d,
1H), 6.873-6.892 (d, 1H), 7.093-7.134 (t, 1H), 7.315-7.369 (q, 2H),
7.403-7.472 (m, 3H), 7.533-7.555 (d, 1H), 7.590 (d, 1H),
7.657-7.660 (d, 2H). m/z (M+H) 485.
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-
methyl butyrate (Example 47, Compound 151
[0218]
(7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihyd-
roquinolin-1(2H)-yl)methyl butyrate (Compound 2) was prepared as
described in Example 16, supra.
##STR00945##
[0219] To a stirred solution of
(7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquin-
olin-1(2H)-yl)methyl butyrate (3.26 g, 5.94 mmol) in THF (100 mL)
was added TFA (2.74 mL, 35.63 mmol) followed by
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ; 7.01 g, 30.88 mmol) in
THF (40 mL). The reaction was stirred at room temperature over the
weekend. The reaction was quenched with water (100 mL) and then
poured into water (600 mL) and dichloromethane (100 mL). Solid
NaHCO.sub.3 (100 g) was added and the mixture stirred for
approximately 30 minutes. Dichloromethane (200 mL) was added and
the mixture filtered. The collected filtrate was transferred to a
separating funnel and the layers separated. The aqueous layer was
extracted with dichloromethane (2.times.100 mL) and the combined
organics washed with water (3.times.100 mL, brine (100 mL) and
dried over MgSO.sub.4. After filtration, the volatiles were
removed. The crude material was purified by silica chromatography
eluting 0-4% Methanol/(1:1 ethyl acetate/dichloromethane). The oil
was recrystallized from methanol to give Compound 151. (2.03 g,
3.72 mmol, 63% yield).
[0220] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.63 (1H, d), 7.45
(1H, d), 7.19-7.06 (2H, m), 6.99-6.90 (1H, m), 6.88-6.78 (2H, m),
6.52 (1H, d), 6.33 (2H, s), 4.06 (2H, t), 3.17-2.99 (4H, bs),
2.74-2.43 (6H, m), 2.35 (2H, t), 1.94-1.54 (6H, m), 0.93 (3H,
t).
The Following Compounds were Synthesized in a Similar Manner to
Example 47 from their Corresponding 3,4 Dihydro Precursors
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-
methyl palmitate (Example 48, Compound 159
[0221] Compound 159 was synthesized in a similar manner to Example
47 from Compound 10.
[0222] 2.04 g. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.62 (1H,
d), 7.44 (1H, d), 7.18-7.10 (2H, m), 6.98-6.91 (1H, m), 6.87-6.80
(2H, m), 6.52 (1H, d), 6.32 (2H, s), 4.05 (2H, t), 3.15-2.99 (4H,
bs), 2.74-2.44 (6H, m), 2.35 (2H, t), 1.92-1.83 (2H, m), 1.80-1.68
(2H, m) 1.66-1.55 (2H, m), 1.32-1.14 (24H, m), 0.87 (3H, t).
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-
methyl laurate (Example 49, Compound 156
[0223] Compound 156 was synthesized in a similar manner to Example
47 from Compound 7.
[0224] 1.37 g. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.62 (1H,
d), 7.43 (1H, d), 7.17-7.10 (2H, m), 6.96-6.92 (1H, m), 6.87-6.80
(2H, m), 6.51 (1H, d), 6.33 (2H, s), 4.06 (2H, t), 3.12-3.01 (4H,
bs), 2.71-2.59 (4H, bs), 2.50 (2H, t), 2.35 (2H, t), 1.92-1.83 (2H,
m), 1.78-1.69 (2H, m) 1.66-1.55 (2H, m), 1.32-1.16 (16H, m), 0.86
(3H, t).
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-
methyl stearate (Example 50, Compound 160
[0225] Compound 160 was synthesized in a similar manner to Example
47 from Compound 11.
[0226] 1.38 g .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.62 (1H,
d), 7.44 (1H, d), 7.17-7.11 (2H, m), 6.97-6.92 (1H, m), 6.87-6.79
(2H, m), 6.51 (1H, d), 6.32 (2H, s), 4.05 (2H, t), 3.13-3.00 (4H,
bs), 2.73-2.58 (4H, bs), 2.50 (2H, t), 2.35 (2H, t), 1.92-1.83 (2H,
m), 1.79-1.69 (2H, m) 1.66-1.55 (2H, m), 1.32-1.14 (28H, m), 0.87
(3H, t).
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-
methyl acetate (Example 51, Compound 150
[0227] Compound 150 was synthesized in a similar manner to Example
47 from Compound 1.
[0228] 1.61 g .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 7.63 (1H,
d), 7.45 (1H, d), 7.18-7.11 (2H, m), 6.98-6.92 (1H, m), 6.90-6.80
(2H, m), 6.52 (1H, d), 6.32 (2H, s), 4.07 (2H, t), 3.14-3.01 (4H,
bs), 2.73-2.59 (4H, bs), 2.51 (2H, t), 2.12 (3H, s), 1.95-1.82 (2H,
m), 1.82-1.68 (2H, m).
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-
methyl 2,2-dimethylbutanoate (Example 52, Compound 165
[0229] Compound 165 was synthesized in a similar manner to Example
47 from Compound 16.
[0230] 1.02 g .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.61 (1H,
d), 7.43 (1H, d), 7.17-7.10 (2H, m), 6.97-6.92 (1H, m), 6.83-6.79
(2H, m), 6.51 (1H, d), 6.31 (2H, s), 4.05 (2H, t), 3.12-3.02 (4H,
bs), 2.71-2.60 (4H, bs), 2.50 (2H, t), 1.92-1.83 (2H, m), 1.78-1.68
(2H, m) 1.55 (2H, q), 1.15 (6H, s), 0.81 (3H, t).
Pharmacokinetic Evaluation in Rats
Pharmakokinetic Evaluation of Prodrugs in Rats Following
Intramuscular Injection
[0231] Animals:
[0232] Male Sprague-Dawley rats (Charles River Laboratories,
Wilmington, Mass.) were obtained. Approximately 24 rats were used
in each study. Rats were approximately 350-375 g at time of
arrival. Rats were housed 2 per cage with ad libitum chow and
water. Environmental conditions in the housing room: 64-67.degree.
F., 30% to 70% relative humidity, and 12:12-h light:dark cycle. All
experiments were approved by the institutional animal care and use
committee.
[0233] Pharmacokinetics Study:
[0234] Rats were dosed IM by means of a 25 gauge, 5/8 in. needle
with 1 cc syringe 0.3 mL suspension was withdrawn from the vial
containing the test compound (see Table E). The mouse was injected
in the muscles of the hind limb after anesthesia with isoflourane.
Blood samples were collected via a lateral tail vein after brief
anesthesia with Isoflurane. A 271/2 G needle and 1 cc syringe
without an anticoagulant was used for the blood collection.
Approximately 350 .mu.L of whole blood was collected at each
sampling time-point of 6 hours, 24 hours and 2, 5, 7, 9, 12, 14,
21, 28, 35 days after administration. Once collected, whole blood
was immediately transferred to tubes containing K2 EDTA, inverted
10-15 times and immediately placed on ice. The tubes were
centrifuged for 2 minutes at >14,000 g's (11500 RPMs using
Eppendorf Centrifuge 5417C, F45-30-11 rotor) at room temperature to
separate plasma. Plasma samples were transferred to labeled plain
tubes (MICROTAINER.RTM.; MFG# BD5962) and stored frozen at
<-70.degree. C.
[0235] Data Analysis:
[0236] Drug concentrations in plasma samples were analyzed by
liquid chromatography-mass spectroscopy using appropriate
parameters for each compound. Half-life, volume of distribution,
clearance, maximal concentration, and AUC were calculated by using
WinNonlin Version 5.2 software.
[0237] Results and Discussion:
[0238] The Results are shown in Table E. As shown in Table E, each
of the compounds tested provides a plasma concentration that is
extended as compared to the parent drug when administered
alone.
TABLE-US-00010 TABLE E API Form used Dose (Compound No.) Excipients
**(mg/kg) AUC.sub.0-14 (ng * day/mL) AUC.sub.0-T (ng * day/mL) 82
solution in ethyl oleate 57 204 NC 2 Recrystallized crystalline 67
1016.9 1139.8 suspention in 1% HPMC in PBS + 0.2% Tween 20 81
solution in ethyl oleate 56 584 NC 48 Milled crystalline suspention
in 70.00 2238 2264.6 1% HPMC in PBS + 0.2% Tween 20. Measured and
diluted to correct concentration* 5 Ethyl oleate emulsion in water
67 1728.6 1742 with DPPC, Glycerol and NCOH 6 solution in ethyl
oleate 67 67 327 6 Oil emulsion in water with DPPC 67 1490.3 1678.1
and Glycerol 47 Milled crystalline suspension in 100.0 113 176 1%
HPMC 85 Milled crystalline suspention in 67 1233.9 1348 1% HPMC in
PBS + 0.2% Tween 20. Measured and diluted to correct concentration
1 Crystalline material suspended in 56.7 1673 1938 1% HPMC 7
Recrystallized crystalline 67 512.0 1169.5 suspention in 1% HPMC in
PBS + 0.2% Tween 20 32 Milled crystalline suspention in 67 1334.4
1486 1% HPMC in PBS + 0.2% Tween 20. Measured and diluted to
correct concentration* 8 Milled crystalline suspention in 24 580.3
666.1 1% HPMC in PBS + 0.2% Tween 20 49 Milled crystalline
suspension in 73.3 152 199.7 1% HPMC 34 Milled crystalline
suspention in 43.33 2050 2095.8 1% HPMC in PBS + 0.2% Tween 20.
Measured and diluted to correct concentration* 79 Prodrug solution
in ethyl oleate 67 954 NC 79 Recrystallized crystalline 67 907.4
940 suspention in 1% HPMC in PBS + 0.2% Tween 20 31 Recrystallized
crystalline 67 819.0 997 suspention in 1% HPMC in PBS + 0.2% Tween
20 10 Recrystallized crystalline 67 302 786.6 suspention in 1% HPMC
in PBS + 0.2% Tween 20 4 Recrystallized crystalline 67 1455.4 1678
suspention in 1% HPMC in PBS + 0.2% Tween 20
Example 53
Pharmacodynamic Studies Using an Amphetamine-Induced Locomotion
Model
Introduction:
[0239] Prodrugs of the invention useful in the treatment of
schizophrenia and bipolar disorder show predictive validity in
rodent models of hyperlocomotion. D-Amphetamine-induced locomotion
is postulated to mimic the dopaminergic hyperactivity which forms
the basis for the "dopamine hypothesis" of schizophrenia. The
AMPH-induced hyperactivity model provides a simple, initial screen
of antipsychotic compound efficacy. See, Fell et al., Journal of
Pharmacology and Experimental Therapeutics, (2008) 326:209-217.
Amphetamine induced hyperactivity was used to screen various doses
of orally administered (PO) prodrug formulations of aripiprazole to
measure pharmacodynamic efficacy in an acute hyperlocomotion
paradigm. The hypothesis of the study is that PO administration of
aripiprazole prodrug formulations, which result in plasma
concentrations of .about.100-200 ng/ml, will produce a significant
attenuation of AMPH-induced locomotion.
[0240] General behavior and activity can be measured in
experimental animals (typically rats and mice) in order to assess
psychomotor stimulant properties, anxiogenic/anxiolytic or sedative
properties of a drug. As such, open-field studies can provide
insight into the behavioral effects of test compounds. Certain
prodrugs of the present invention are useful in the treatment of
schizophrenia and bipolar disorder. Aripiprazole is a parent lactam
containing drug from which some of the prodrugs of the invention
are derived that is useful in the treatment of schizophrenia and
bipolar disorder. Such aripiprazole prodrugs of the invention show
predictive validity in rodent models of hyperlocomotion.
D-Amphetamine-induced locomotion is postulated to mimic the
dopaminergic hyperactivity which forms the basis for the "dopamine
hypothesis" of schizophrenia. Likewise, glutamate NMDA receptor
antagonist (MK-801, PCP, etc.) induced locomotion is postulated to
mimic the NMDA hypoactivity hypothesis of schizophrenia (Fell et
al., supraa). These tests of drug-induced hyperactivity provide
simple, initial screens of antipsychotic compound efficacy.
Amphetamine induced hyperactivity will be used to screen various
prodrugs of aripiprazole, administered PO in oil solutions, to
measure pharmacodynamic efficacy. The results of the D-AMPH induced
locomotion done in this study will be compared to the historical
results of subcutaneous (S.C.) aripiprazole administration on
D-AMPH. The hypothesis of the study is that PO exposure to
aripiprazole prodrugs, which results in aripiprazole concentrations
of 100-200 ng/ml at locomotor testing, will display efficacy in
in-vivo measures of antipsychotic efficacy.
[0241] Materials:
[0242] Experimental animals: 12, Sprague Dawley rats were purchased
from Charles River Laboratory. The rats were approximately 90 days
old, and weighed in the range of 350-275 grams upon receipt from
the supplier. One rat was placed in a cage and allowed to acclimate
for about 1 week. The rats were provided with food and water ad
libitum.
[0243] Dosing Solution of D-Amphetamine (D-AMPH):
[0244] D-AMPH was purchased from Sigma Aldrich. D-amphetamine HCl
was prepared in 0.9% saline to a concentration of 1.5 mg/ml.
D-Amphetamine was given I.P. per body weight at a dose of 1 ml/kg
(=1.5 mg/kg). Salt form correction was not used in accordance with
historical literature. D-Amphetamine was prepared fresh from solid
form 30 min. prior to each test period.
Dosing Solutions of Prodrug Derivatives of Aripiprazole:
TABLE-US-00011 [0245] TABLE F Dose Study Dose volume Group
Formulation (Route) mg/rat mL N A Arp-laurate oral oil 7.5 1.5 4
Solution (PO) B Arp-Hexanoate oral oil 20 1.5 4 Solution (PO) C
Arp-Hexanoate oral oil 10 1.5 4 Solution (PO) D Arp-laurate oral
oil 10 1.5 4 Solution (PO) E Arp-Hexanoate oral oil 0.66 1.5 4
Solution (PO) F Arp-Laurate oral oil 20 1.5 4 Solution (PO) G
Saline (PO) 0 1.5 4
[0246] Behavior Box:
[0247] The behavior chambers were purchased from Med Associates,
Inc. of St. Albans, Vt., Model ENV-515. Software for measuring
animal movement is provided with the behavior chamber by the
supplier.
[0248] Methods:
[0249] Following 1 week habituation to the animal facility, the
activity assessments commenced. The animals were initially
acclimated to the behavior box for about 15 minutes before they
were removed from the box and injected PO with 1.5 ml of an
aripiprazole prodrug compound of the invention, at concentrations
which produce PK levels of 100-200 ng/ml approximately 1 hour after
administration. After an additional 15 minutes the animals were
placed back in the behavior box for an additional 30 minute
drug-baseline test session. The mice were then administered by IP
injection, D-AMPH (1.5 mg/kg) followed by a 60 minute experimental
behavorial measurement period. The parameters that were measured
were a) total distance measured (primary measure), b) total number
of ambulatory moves (secondary measure), c) total number of
vertical moves (secondary measure) and d) time spent immobile
(secondary measure).
[0250] Blood Sampling:
[0251] Tail vein blood was taken on experiment days immediately
following locomotor activity measurements (2-hours post-prodrug
administration) and again the following day a time-point
corresponding to 22 hours post-prodrug administration. Blood
samples were collected via a lateral tail vein after anesthesia
with Isoflurane. A 271/2 G syringe without an anticoagulant was
used for the blood collection, and the whole blood transferred to
pre-chilled (wet ice) tubes containing K2 EDTA. 0.5 ml of blood per
animal was collected per time point. The tubes were inverted 15-20
times and immediately returned to the wet ice until being
centrifuged for 2 minutes .gtoreq.14,000 g to separate plasma. The
plasma samples prepared in this manner were transferred to labeled
plain tubes (MICROTAINER.RTM.; MFG# BD5962) and stored frozen at
<-70.degree. C.
[0252] Behavioral Data Acquisition:
[0253] Behavioral data was captured electronically by the software
package associated with the behavior chambers. Data was transformed
and analyzed via GraphPad PRISM.RTM. 5 software (GraphPad Software,
Inc., La Jolla, Calif.). The data was analyzed using a 2-way
repeated measures ANOVA.
Results and Discussion:
[0254] The results are shown in FIGS. 6 and 7. The results indicate
that orally administered D-AMPH caused a significant increase in
the total distance traveled by the mice as compared to mice who
were administered only saline. The results also indicate that
aripiprazole prodrug compound 4 of the invention significantly
inhibited the increases in distance traveled caused by D-AMPH. The
inhibition of distance traveled by compound 4 did not appear to be
dose dependent. Likewise, aripiprazole prodrug compounds 7 and 47
did appear to significantly inhibit increases in distance traveled
caused by D-AMPH at the higher dose of 20 mg. This data indicates
that in accordance with the invention, the prodrug compounds are
cleaved in vivo to release the parent tertiary amine-containing
drug (aripiprazole in this example) to provide the expected
pharmacological effects on the animal.
[0255] The patent and scientific literature referred to herein
establishes the knowledge that is available to those with skill in
the art. All United States patents and published or unpublished
United States patent applications cited herein are incorporated by
reference. All published foreign patents and patent applications
cited herein are hereby incorporated by reference. All other
published references, documents, manuscripts and scientific
literature cited herein are hereby incorporated by reference.
[0256] While this invention has been particularly shown and
described with references to preferred embodiments thereof, it will
be understood by those skilled in the art that various changes in
form and details may be made therein without departing from the
scope of the invention encompassed by the appended claims.
* * * * *